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Abstract 
Signal transduction pathways are mainly depending on phosphorylation events, which 
are controlled by the activity of phosphatases and kinases. Although kinases have been 
widely studied, however, much less is known about the contribution of phosphatases 
to the regulation of cell signalling pathways. Leukocyte common antigen-related 
protein (LAR) is a member of the LAR subfamily of receptor-like protein tyrosine 
phosphatases (RPTPs). LAR is involved the regulation of a number of receptor 
tyrosine kinases (RTKs) including platelet-derived growth factor receptor (PDGFbR). 
To gain insight into the signaling pathways regulated by LAR, including those that are 
PDGF-dependent, we have carried out the first systematic analysis of LAR-regulated 
signal transduction using SILAC-based quantitative proteomic and phosphoproteomic 
techniques. The differential phosphorylation between wild-type mouse embryo 
fibroblasts (MEFs) and MEFs in which the LAR cytoplasmic phosphatase domains 
had been deleted (LARDP) was analysed. A significant change in abundance of 
phosphorylation on 270 phosphorylation sites from 205 proteins was associated with 
the lack of LAR phosphatase activity. Gene ontology analysis revealed an enrichment 
of LAR-mediated phosphorylation events on proteins involved in many signalling 
transduction pathways including those regulating the actin cytoskeleton, cell adhesion, 
endocytosis and cell metabolism. Analysis of putative kinases upstream of LAR-
dependent phosphorylation events revealed a role for LAR in regulating signalling 
through mTOR and JNK. In summary, this thesis identifies an important role for LAR 
phosphatase in the regulation of signal transduction, cell adhesion and cell metabolism. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. Platelet-derived growth factors 
1.1.1. Introduction	
	
Platelet-derived growth factor (PDGF) was firstly isolated from human platelets and 
is expressed in all organs with the highest level in the heart and placenta (Fredriksson 
et al., 2004, Ross, 1986). Many activities that occur in cells, such as growth, survival, 
motility, proliferation and differentiation, are regulated by growth factors. PDGF is a 
dimeric molecule that is composed of disulfide bonded A, B, C and D isoforms. PDGF 
has been shown to make a homodimeric (PDGF-AA, PDGF-BB) and heterodimeric 
(PDGF-AB). These PDGF isoforms bind to Platelet-derived growth factor receptor ɑ 
(PDGFɑR) and Platelet-derived growth factor receptor β (PDGFβR). PDGFɑR binds 
to isoforms A, B and C whereas PDGF β receptor binds to ligands B and D (Heldin et 
al., 1998). Since the ligands are dimeric molecules thus have two-receptor epitopes 
bind to the two receptors leading to receptor dimerization and oligomerization (Duan 
et al., 1991).  
PDGF AA gives rise to the dimerization of PDGFRαα, while BB leads to αα and ββ 
dimer, CC ligand form αα and DD induces ββ dimerization (Figure 1.1). Both, 
PDGFR α and PDGF β receptor consist of five extracellular immunoglobulin domains 
and intracellular domains with tyrosine kinase activity (Kanakaraj et al., 1991).  
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An important function of dimerization is to activate PDGF receptor by allowing the 
autophosphorylation of certain tyrosine residues (see section 1.2) located in the 
intracellular domains (Jiang and Hunter, 1999). 
 
 
Figure 1.1. The specificity of PDGF and their receptors. PDGF AA gives rise to the 
dimerization of PDGFRαα, while BB leads to αα and ββ dimer, CC ligand form αα and DD 
induces ββ dimerization. Adapted from (X. Li and Eriksson, 2003).	
 
 
PDGF-AA PDGF-BB PDGF-CC PDGF-DD
PDGF isoform
Receptor type αα β β
Kinase domain Immunoglobulin domain Transmembrane domain 
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PDGF has been shown as a stimulator of cellular processes in cells of mesenchymal 
origin. PDGF and their receptors are expressed in most tissues (Heldin and 
Westermark, 1999). PDGFs are highly mitogenic molecules during embryonic stages 
leading to cell proliferation and differentiation. PDGF and PDGFR play a crucial role 
in later maturation stages including wound healing, constriction of blood vessels, 
angiogenesis, cell migration and tissue remodelling (Fredriksson et al., 2004, Hellberg 
et al., 2010). Several studies have shown that PDGFβR stimulates chemotaxis (Hansen 
et al., 1996). In contrast, PDGFαR plays an inhibitory role in chemotaxis signal in 
many cell types (Koyama et al., 1996, Siegbahn et al., 1990, Yokote et al., 1996).  
 
 
1.1.2. Platelet-derived growth factors in disease 
	
PDGFs and corresponding receptors were expressed in most cells and tissues (Guha et 
al., 1995, Heldin, 1992, 2013, Heldin et al., 2016). In contrast, overexpression of the 
PDGF receptors has been reported to cause several diseases such as atherosclerosis 
and cancer. Previous research findings from animal studies indicated that knockout of 
PDGF or PDGFR can cause disorders such as defective of alveoli development in lung, 
abnormality in cerebral vascularization, and also defective in the development of blood 
vessels (Hoch and Soriano, 2003). 
A considerable amount of literature has been published on diseases caused by PDGF 
receptor overactivation including breast cancer, glioblastoma, sarcoma, 
atherosclerosis and renal fibrosis (Aguilar, 2016, Alehagen et al., 2016, Appiah-Kubi 
et al., 2016, Lewandowski et al., 2016a, Lewandowski et al., 2016b, Pietras et al., 
4	
	
2003). It has also been reported that overactivation of PDGF and PDGFR linked to 
breast cancer and the inhibition of PDGFR reduced the invasion of the cancer cells 
(Paulsson et al., 2009). PDGF and their receptors have been identified in glioblastoma 
multiforme (GBM) cell lines suggested the autocrine activity caused by PDGF 
stimulation leading to development of glioblastoma multiforme (Hermanson et al., 
1992, Lokker et al., 2002). 
According to animal studies, the hyperactivity of PDGF has also been reported to 
induce oligodendroglial tumor and many brain tumours. Chronic myeologenous 
leukaemia has linked to PDGFβR overexpression (Appolloni et al., 2009, Dai et al., 
2001). Moreover, PDGF is upregulated in prostate carcinoma and liver cancer and the 
inhibition of PDGFR kinase activity by imatinib or sunitinib was shown to reduce cell 
migration and tumor progression (Gotzmann et al., 2006, Ko et al., 2001). These 
finding demonstrate that PDGF and PDGFβR overactivation enhance the development 
of cancer and invasiveness. Overexpression of PDGFβR has also reported in lung 
cancer, demonstrating a crucial role for PDGF and their receptor in the development 
of lung cancer (Tsao et al., 2011).  
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1.1.3. PDGFβR downregulation 
1.1.3.1. Dephosphorylation by protein tyrosine phosphatases	
 
PDGFβR signalling is highly controlled through several mechanisms; one of them is 
the dephosphorylation by protein tyrosine phosphatases (PTPs). It has been identified 
that many of PTPs bind with and dephosphorylate several selected tyrosine residues 
on PDGFβR to terminate the receptor downstream signalling molecules. For example, 
Low molecular weight protein tyrosine phosphatase (LMW-PTP) has been found to 
dephosphorylate Tyr857 on PDGFβR to inhibit the receptor kinase activity (Chiarugi et 
al., 2002). In addition, LMW-PTP can also dephosphorylate Tyr716 on the receptor 
leading to prevent the interaction of Grb2 (Chiarugi et al., 2002). 
T-cell protein tyrosine phosphatase (TC-PTP) can dephosphorylate Tyr1021 on 
PDGFβR, which is a binding site of phospholipase C gamma1 (PLCγ1), leading to 
decreased cell migration in response to PDGF (Persson et al., 2004). Grb2 can bind to 
Tyr716 on PDGFβR and form a complex with Sos1 in order to activate Ras signalling 
(Schlessinger, 1993). Ras-GAP has been shown to binds with PDGFβR at Tyr771 (Fantl 
et al., 1992, Kashishian et al., 1992) which in turn deactivates the Ras signalling 
pathway by converting the active form of Ras-GTP to Ras-GDP (van der Geer et al., 
1997). However, SHP-2 can dephosphorylate the binding site of Ras-GAP Tyr771 
leading to enhance the activity of Ras signalling pathway by preventing Ras-GAP 
interacting with PDGFβR (Ekman et al., 2002). 
Moreover, PTP1B dephosphorylates Tyr579 residue of PDGFβR where Src and Shc can 
bind, to terminate the signalling initiation by these proteins (Ekman et al., 2002, 
Persson et al., 2004). Histidine domain-containing protein tyrosine phosphatase (HD-
PTP) is recruited to the PDGFβR in response to PDGF-BB and is required for 
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PDGFβR degradation  (H. Ma et al., 2015a). In summary, protein tyrosine 
phosphatases play an important role in regulating PDGFβR signalling.  
 
 
1.1.3.2. Serine phosphorylation 
	
Serine phosphorylation is also a key regulator of the receptor tyrosine kinases to 
desensitize receptor activity such as insulin receptor (IR) and EGFR after stimulation 
(Countaway et al., 1992, Takayama et al., 1988). It has been reported that some 
serine/threonine kinases can phosphorylate the serine residues on PDGFβR leading to 
decreased activity of the receptor by reducing the autophosphorylation rate (Bioukar 
et al., 1999). For instance, Casein kinase Iγ2 (CKIγ2) is serine/threonine kinase that 
can regulate PDGFβR activity by phosphorylating serine residues on the receptor 
(Bioukar et al., 1999). 
Several studies have published on the importance of G protein-coupled receptor kinase 
2 (GRK2) for regulating receptor desensitization and internalization. GRK2 is one of 
seven members of the GRK family (GRK1-GRK7), which are widely expressed in 
mammalian tissue and regulate a variety of cellular effects (Black et al., 2016). GRK2 
regulates PDGFβR by mediating serine phosphorylation leading to receptor 
desensitization and a reduction in receptor autophosphorylation (J. H. Wu et al., 2005). 
A GRK2 inhibitor restored tyrosine phosphorylation of the PDGFβR but not EGFR 
demonstrating a significant role of the GRK2 in regulating PDGFβR signalling 
(Freedman et al., 2002). GRK2 translocates to the plasma membrane by an interaction 
with Gβγ subunits and PIP2 in order to activate GRK2 (Pitcher et al., 1998). On the 
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other hand, GRK2 and GRK5 have a specific sequence for binding to Ca2+/calmodulin 
leading to inhibition of their activity suggesting an alternative mechanism to regulate 
GRK2 activity (Pronin and Benovic, 1997).  
 
 
 
1.1.3.3. PDGFβR internalization and degradation 
	
PDGFβR can also be downregulated by ubiquitination and internalization. Upon 
activation, PDGFβR is internalized and sorted for the lysosomal degradation. The 
internalization and intracellular sorting of the cell membrane components such as 
epidermal growth factor receptor (EGFR) and PDGFR have been characterized 
(Maxfield and McGraw, 2004). In general, RTKs are trafficked to the early endosomes 
and at this point some receptor rapidly recycle back to the membranes via Rab4a 
GTPase (Maxfield and McGraw, 2004). By using Rab11 dependent endocytosis, some 
receptors are sorted and recycling to reach a long recycling loop to the cell membrane 
such as EGFR (Dikic, 2003, Waterman and Yarden, 2001). Other receptors reach late 
endosomes to lysosomal degradation (van Ijzendoorn, 2006). The termination and 
sorting of the receptors signalling toward lysosomal degradation depends on the 
interaction of the receptors with hepatocyte growth factor regulated tyrosine kinase 
substrate (Hrs) and endosomal sorting complex required for transport I (ESCRT I) 
(Bache et al., 2003, Raiborg et al., 2003). Hrs can bind with signal transducing adapter 
molecule 2 (STAM2) and promote PDGF-induced PDGFβR degradation (Takata et 
al., 2000). The Cbl family of E3 ubiquitin ligases have been shown to induce PDGFβR 
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ubiquitination and degradation by sorting receptor towards lysosomal degradation 
(Miyake et al., 1999, Schmidt and Dikic, 2005).  
The kinase activity of PDGFβR is required for PDGF-induced internalization (Mori et 
al., 1993). Later, researchers have found short amino acid sequences 952–965 essential 
for the receptor internalization (Pahara et al., 2010). It has been reported that activation 
of protein kinase C α (PKCα), the downstream of PDGFβR, is required for the 
PDGFβR recycling via Rab4a-dependent manner (Hellberg et al., 2009).  
 
 
1.2. Signal transduction pathways 
	
The interaction of PDGF and PDGF receptor leads dimerization and 
autophosphorylation of specific tyrosine residues on the receptor in trans. This initiate 
a cascade of signal transduction leading to modulation of cellular functions such as 
cytoskeletal rearrangement, gene transcription, proliferation, ion channel activation 
and cell movement.  
Autophosphorylation is an important mechanism and plays a key role in receptor 
kinase activity by provide docking sites for the downstream transduction molecules. 
Several studies have revealed that there 11 out of 15 tyrosine residues situated in the 
intracellular domain (non-catalytic) of the PDGFβ receptor and are considered as 
autophosphorylation sites (Figure 1.2) (Claesson-Welsh, 1994). PI3K binds to the 
PDGFβR tyrosine sites Tyr740 and Tyr751 (Fantl et al., 1992, Kashishian et al., 1992). 
Phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) is a substrate for the PI3K which 
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can be converted to the PI(3,4,5)P3  (Vassbotn et al., 1992). PI(3,4,5)P3 phosphorylates 
Tyr308 on Akt/PKB leading to initiates Akt/PKB signalling (Klippel et al., 1997). 
Phospholipase C (PLCγ) is another important example which produce two molecules 
by using PI(4,5)P2 as a substrate. Firstly, inositol (1,4,5) trisphosphate which increased 
the concentration of cytoplasmic Ca2+, and secondly, diacylglycerol that leads to 
protein kinase C activation (Berridge, 1993). Taken together, the activation of 
Akt/PKB and PLC-γ via PDGF receptor leading to certain cellular functions such as 
cytoskeletal rearrangement, gene transcription, proliferation, ion channel activation 
and cell movement. In addition, Src kinases, Ras-GAP, are also involved in signalling 
network as well as adaptor molecules including Grb2, Grb7, Shc, Nck, Crk, 
SAPK/JNK and STATS (Heldin and Lennartsson, 2013). 
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Figure 1.2. PDGFβR dimerization and interaction with signal transduction molecules. 
Shows autophosphorylation tyrosine residues and the known binding SH2 containing 
downstream proteins.  
 
 
	
	
 
Tyr579 
Tyr581
Tyr716 
Tyr740
Tyr763 
Tyr751
Tyr771 
Tyr775
Tyr1009 
Tyr1021 
Src 
Autophosphorylation site Kinase domain 
PDGF 
Grb7
P
P
Grb2
SHP2
 P RasGAP
PDGFβR 
P
PLCγ 
p85/p110  
11	
	
1.2.1. PI3K/Akt pathway 
	
PI3Ks are a family of cytoplasmic kinases that enable to phosphorylate the 3′-position 
(hydroxyl group) of phosphoinositides. PI3Ks are classified into three distinct groups 
(Bayascas and Alessi, 2005, Engelman et al., 2006, McManus et al., 2004). Class I 
PI3K can be activated in response to multiple stimuli such as G-protein-coupled 
receptors, Ras or growth factors (e.g. PDGF) (Cantley, 2002). PI3K class I 
phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) leading to the production 
of phosphatidylinositol-3,4,5-trisphosphate (PIP3) (Cantley, 2002, Vanhaesebroeck 
and Alessi, 2000). Whereas class II and class III produce phosphatidylinositol-3-
phosphate PI-3-P by using phosphatidylinositol (PI) as a substrate (Bago et al., 2014, 
Engelman et al., 2006).  
PI3K class II and III are mainly involved in regulation of membrane trafficking, 
endocytosis, phagocytosis and can be activated in response to integrins, cytokines and 
growth factors (Backer, 2008, Bago et al., 2016, Engelman et al., 2006). PI3K class I 
have been shown to bind and become activated by PDGFβR (Auger et al., 1989, 
Coughlin et al., 1989, Kazlauskas and Cooper, 1989). PI3K class I consist of catalytic 
subunit p110 and regulatory subunit p85 with two SH2 domains (Songyang et al., 
1993). Two autophosphorylated tyrosine residues in the PDGFβR and PDGFαR 
Tyr740, Tyr751 are the binding sites for PI3K class I (Fantl et al., 1992, Kashishian et 
al., 1992, Kazlauskas et al., 1992, Yu et al., 1991).  
After the activation of PI3K by PDGFβR, PI3K generate PI(3,4,5)P3 which in turn 
recruits PH (Pleckstrin homology) domain containing proteins, such as Akt (Figure 
1.3) (Alessi et al., 1996, Burgering and Coffer, 1995). This causes a conformational 
change leading to the activation of Akt by phosphorylation of two residues, Thr308 via 
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phosphoinositide dependent kinase 1 (PDK1) (Franke et al., 1997, Stokoe et al., 1997) 
and Ser473 via mTORC2 (Feng et al., 2004, Persad et al., 2001, Sarbassov et al., 2005). 
Akt has been shown to regulate many downstream proteins. For example, Akt 
phosphorylates Bcl-2 family protein BAD (Bcl-2/Bcl-XL-antagonist, causing cell 
death) which leads to suppression of apoptosis by preventing the interaction of BAD 
with Bcl-2 or Bcl-XL, the unphosphorylated form of BAD can bind to BLCXL leading 
to apoptosis (Datta et al., 1997, Vanhaesebroeck and Alessi, 2000, Zha et al., 1996). 
Researchers examined whether PDGFβR activation prevents apoptosis by transfecting 
rat adrenal gland (PC-12) cells with Y740F mutant PDGFβR (lacks the binding site of 
PI3K) and they found these cells are unable to prevent apoptosis (R. Yao and Cooper, 
1995). This notion supports the fact that PDGF β-receptor is important not only for 
proliferation and many other functions but also protects the cells from undergoing 
apoptosis. 
In addition, Akt has been shown to regulates mammalian target of rapamycin (mTOR) 
by two ways; First, by phosphorylation and suppression of the activity of tuberous 
sclerosis complex 2 (TSC2), a negative regulator of mTOR; and second, by inhibition 
of the activity of AMP-activated protein kinase (AMPK), an activator of TSC2 (Hahn-
Windgassen et al., 2005, Hay and Sonenberg, 2004). PI3K has been found to be 
involved in many biological processes in response to PDGF stimulation including actin 
reorganization, cell movement, cell growth and the suppression of cell survival 
(Kamohara et al., 1995).  
Signalling through PI3K/Akt also contributes to angiogenesis via the activation of 
endothelial nitric oxide synthase (eNOS) in endothelial cells and also involved in 
Glucose Metabolism (Kamohara et al., 1995, Manning and Cantley, 2007). Recently, 
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researchers showed that hyperactivity of Akt is linked to increased breast cancer 
recurrence rate by the inhibition of FOXO3a, Forkhead transcription factor (also 
known as FKHRL1). FOXO3a can prevent mammospheres formation which is 
responsible for metastasis and retrieval of the tumor in breast cancer stem cells (BCSC) 
(Smit et al., 2016). 
The PI3K/Akt pathway is highly controlled by dephosphorylation of Akt at Ser473 by 
PH domain and Leucine rich repeat Protein Phosphatases (PHLPP) and at Thr308 by 
protein phosphatase 2A (PP2A) to downregulate Akt activity (Carracedo and Pandolfi, 
2008, Osaki et al., 2004). Akt signalling can also downregulated by phosphatase and 
tensin homolog (PTEN). PTEN terminates PI3K signalling by dephosphorylation of 
PIP3 (Carracedo and Pandolfi, 2008, Chalhoub and Baker, 2009). 
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Figure 1.3. Schematic representation of the PI3K/Akt pathway. PI3K class I isoforms bind to 
phosphorylated Tyr740 or Tyr751 on PDGFbR. PI3K can phosphorylate phosphatidylinositol-4,5-
bisphosphate (PIP2) leading to the production of phosphatidylinositol-3,4,5-trisphosphate (PIP3). 
PIP3 recruits PH (Pleckstrin homology) domain containing proteins, such as Akt. This causes a 
conformational change leading to the activation of Akt by phosphorylation of two residues, first, 
Thr308 via PDK1 and second, Ser473 via mTORC2.  
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1.2.2. PLCγ pathway 
	
Phospholipase C (PLCγ) is activated after binding to PDGFβR (Heldin et al., 1998). 
PLCγ produces two molecules by using PI(4,5)P2 as a substrate; inositol (1,4,5) 
trisphosphate which increases the concentration of cytoplasmic Ca2+; and 
diacylglycerol that leads to protein kinase C activation (Berridge, 1993) (Figure 1.4). 
There are two isoforms of PLCγ, PLCγ1 and PLCγ2 each with two SH2 domains and 
one SH3 domain (Kamat and Carpenter, 1997, Sultzman et al., 1991). PLCγ1 binds to 
the phosphorylated Tyr1009 and Tyr1021 on PDGFβR (Kashishian and Cooper, 1993, 
Valius et al., 1993). Upon binding with PDGFβR, PLCγ1 is phosphorylated on Tyr783 
for activation (Kim et al., 1991).  
PDGFβR has been shown to stimulate the differentiation of monocytes in response to 
PDGF-BB and this effect was diminished by the mutation of Tyr1021 to phenylalanine 
residue, suggesting that the PLCγ pathway is essential for the differentiation (Heldin 
et al., 1998). PLCγ is also involved in the activation of the Na+/H+ exchanger (NHE) 
in presence of Ca2+ and PKCs (Y. H. Ma et al., 1994). It has been demonstrated the 
importance of PLCγ in several physiological functions such as cytoskeletal 
reorganization, activation of ion channels and involved in PDGF-dependent cell 
growth and motility (Hansen et al., 1996, Ji et al., 2015, Kundra et al., 1994, Y. H. Ma 
et al., 1994). Additionally, PLCγ has been indicated to play a crucial role in 
differentiation of hematopoietic stem cells by regulating the activity of histone variant 
macroH2A2 (mH2A2) (Schnoder et al., 2015). 
 PLCγ is involved in the activation of phosphatidylcholine-specific phospholipase D 
(PLD) leading to generation of diacylglycerol (DAG) (Jones and Carpenter, 1993, Y. 
H. Lee et al., 1994, Yeo et al., 1994). DAG  is essential for the activation of PKCs in 
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response to PDGF-BB (Plevin et al., 1991). Researchers have been reported that PKCδ 
can be activated by association to the diacylglycerol and phorbol ester (Castagna et al., 
1982, Michell, 1975). Nevertheless, PKCδ can be phosphorylated on different residues 
and this leads to either activation or inactivation of catalytic activity of the enzyme 
(Okhrimenko et al., 2005, Zrachia et al., 2002). Src family kinases, c-Abl and Ras have 
shown to phosphorylate tyrosine sites and increase PKCδ activity in response to 
PDGF, EGF, and PMA. PKCδ promotes cell cycle arrest by downregulates cyclin D1 
and cyclin E (Ashton et al., 1999, Fukumoto et al., 1997), suggesting that PKCδ 
decreases cell proliferation. 
PKCδ has been reported to play an important role in regulation of insulin signalling in 
skeletal muscle (M. Li et al., 2015c). In addition, PKCδ can induces apoptosis by 
regulate the activity of TA isoforms of p63 (TAp63) and this occurs by 
phosphorylation of TAp63 at Thr157 (D. Li et al., 2015a). Recently, researchers 
described that knockout of PKCδ in mice caused a significant defect in fertility and 
embryonic development suggesting a fundamental role for PKCδ in regulation of 
reproductive system (W. Ma et al., 2015b). PKCδ can be phosphorylated and activated 
by c-Abl (Lu et al., 2007). c-Abl phosphorylates Tyr311 on PKCδ upon H2O2 induction 
leading to apoptosis (Lu et al., 2007). 
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Figure 1.4. Schematic representation of the PLC-γ pathway. PLCγ binds to the phosphorylated 
Tyr1009 and Tyr1021 on PDGFβR. PLCγ produces two molecules by using PI(4,5)P2 as a 
substrate; inositol (1,4,5) trisphosphate which increases the concentration of  Ca2+; and 
diacylglycerol that leads to protein kinase C activation.  
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1.2.3. Ras pathway 
	
Grb2 is an adaptor molecule with one SH2 domain and two SH3 domains and has been 
shown to bind directly to the autophosphorylated Tyr716 on the PDGFβR (Arvidsson 
et al., 1994). Grb2 forms a complex with Sos1 in order to activate Ras by converting 
Ras from inactive GDP-bound form to its active GTP-bound form (Figure 1.5) 
(Schlessinger, 1993). The activation of Ras in response to PDGF stimulation leading 
to initiate a cascade of signalling transduction whereby Ras-GTP activates Raf-1 by 
binding with regulatory N-terminal part of Raf-1 (Nanberg and Westermark, 1993, 
Satoh et al., 1993). On the other hand, GAP can bind to the phosphorylated Tyr771 of 
the PDGFβR (Fantl et al., 1992, Kashishian et al., 1992, van der Geer et al., 1997) to 
converts Ras from active GTP-bound form to its inactive GDP-bound form in order to 
deactivates Ras signalling. Ras activation occurred either via direct binding of 
Grb/Sos1 to Tyr716 on the receptor or indirect binding of the complex Grb/Sos1 to the 
phosphorylated Shc (Heldin et al., 1998). Moreover, several studies have revealed that 
Ras act as anti-apoptotic factor by mediating PI3K activation (Kauffmann-Zeh et al., 
1997). 
Raf-1 phosphorylates and activates Mek which then phosphorylates and activates 
MAP kinases Erk1 and Erk2. Erk1/2 then translocated into the nucleus to regulate 
many transcription factors (Nanberg and Westermark, 1993, Satoh et al., 1993). Erk5 
can also be activated via Mek and Mekk2 in response to PDGF stimulation 
(Tsioumpekou et al., 2016). Because of the Ras and MAP kinase activation caused by 
PDGF, PDGFβR has been shown to play important role in cell growth. 
Grb2 has also been shown to bind indirectly to the PDGFβR via adaptor protein Shc 
and tyrosine phosphatase SHP-2 (Benjamin and Jones, 1994, W. Li et al., 1994a, 
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Yokote et al., 1994). Upon stimulation with PDGF, these proteins bind to the PDGFβR 
and become phosphorylated on tyrosine sites present within the pYXNX motifs. This 
phosphorylation then leads to recruitment of Grb2 and Sos1 for the activation of Ras 
signalling pathway.  
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Figure 1.5. Schematic representation of the Ras pathway. Grb2/Sos1 complex binds to 
phosphorylated Tyr716 residue on PDGFbR in order to activate Ras by converting Ras from 
inactive GDP-bound form to its active GTP-bound form. This leads to initiating MAPK/ERK 
signalling pathway. 
 
 
In addition, Ras can also activate the small GTP binding proteins Rho, Rac and Cdc42 
demonstrating cross-talk between different signalling pathways (Khosravi-Far et al., 
1995, Olson et al., 1995, Qiu et al., 1997, Qiu et al., 1995). The activation of MAP 
kinase cascade by Ras has been reported to play an important role in regulating cell 
growth, cell migration and differentiation (Fanger et al., 1997, Ruusala et al., 1998, 
 
PDGF 
Y716 Grb2/Sos1
Ras-GDP
Ras-GTP
Raf1
MEK
ERK1/2
PI3K
Akt
PDK1RhoA RacPLC
PKC
Calcium signalling
Cytoskeletal 
organization Survival Proliferation
GAP
21	
	
Seger and Krebs, 1995). Ras can also regulate focal adhesion via Src. Src is a member 
of a family of tyrosine kinases that has been shown to be activated after interacting 
with phosphorylated Tyr579 or Tyr581 on PDGFβR (Mori et al., 1993). Since the 
physiological response of the cell adhesions is mainly regulated by focal adhesion 
kinase (FAK), the association of ECM with integrin leads to autophosphorylation of 
FAK at Tyr397 to facilitate interaction with Src (Parsons, 2003). This interaction in turn 
results into another round of phosphorylation of FAK at Tyr407, which results in 
phosphorylation of paxillin at Tyr118 (Bellis et al., 1995, Schaller and Parsons, 1995). 
Signalling initiated by FAK can then lead to the activation of several downstream 
proteins (Abbi and Guan, 2002, Schlaepfer et al., 1999).  
Moreover, Ras can act as anti-apoptotic factor through the activation of Akt via PI3K 
and NF-κB (Downward, 1998, Kauffmann-Zeh et al., 1997). Ras can also signal to the 
JNK pathway via Tripartite Motif-containing 7 (Trim7) to regulate transcription and 
tumor progression (Chakraborty et al., 2015). Ras pathway has been found 
hyperactivated in cancers. For instance, Ras has been found upregulated in acute 
myeloid leukaemia (AML) suggesting Ras as one of the most enriched pathway 
responsible to initiates leukemogenesis (Z. Zhao et al., 2015b). In addition, researchers 
have been described that 32% of lung adenocarcinoma is driven by Ras (McCormick, 
2015). Furthermore, 78% of patients with neuroblastoma showed upregulation of Ras 
pathway (Eleveld et al., 2015). 
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1.2.4. JNK pathway 
C-Jun N-terminal kinase (JNK) is a serine/threonine kinase which is activated by a 
broad range of external stimuli including PDGF, transforming growth factor-β, and 
environmental stress (Kyosseva, 2004). There are three genes that encode for JNK; 
Jnk1, Jnk2, and Jnk3 (Davis, 2000). Stimulation by PDGF leads to activation of JNK 
through Rac GTPase signalling (Figure 1.6) (Amagasaki et al., 2006, Bagrodia et al., 
1995, Kyriakis, 1999). The JNK signalling pathway is involved in many cellular 
functions including inflammation, apoptosis and differentiation (Barr and 
Bogoyevitch, 2001, Y. T. Ip and Davis, 1998). For example, the inhibition of JNK 
activity significantly reduced inflammation in atherosclerosis-induced mice 
demonstrating a key role for JNK signalling pathway in preventing inflammation in 
adipose tissues (Kwok et al., 2015). JNK is also involved in regulating of migration 
and enhance chemotaxis in response to PDGF-BB stimulation (Amagasaki et al., 
2006).  
MKK4 and MKK7 activate JNK by the phosphorylation of tyrosine and threonine 
residues (Lawler et al., 1998). MKK4 phosphorylates Tyr185 whereas MKK7 
phosphorylates Thr183 in response to cellular stress for full activation (Davis, 2000, 
Lawler et al., 1998). Genetic studies demonstrated that knockout of either MKK4 or 
MKK7 genes prevent the activation of JNK upon stimuli (Tournier et al., 2001). Upon 
activation, JNK can phosphorylate its downstream effector c-Jun on two sites Ser63 
and Ser73, within the activation loop leading to a transcriptional affect (Weston and 
Davis, 2002). Mutation of these residues to Alanine leads to disruption of the 
activation of c-Jun (Behrens et al., 2000, Behrens et al., 1999).  
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It has also been reported that JNK signalling is regulated by scaffold proteins such as 
filamin, β-arrestin and CrkII. For instance, JNK can interact with CrkII in order to be 
activated by Rac1 (Girardin and Yaniv, 2001). In addition, filamin can associate with 
MKK4 and MKK7 to contribute to the activation of JNK signalling (Marti et al., 1997). 
JNK can phosphorylate and activate the oncoprotein 18 (stathmin1) suggesting a key 
role of JNK in regulating microtubules (Ng et al., 2010). 
Dual specificity phosphatases (DSP), a subfamily of PTPs have been shown to 
inactivate JNK signalling pathway by dephosphorylation of Tyr and Thr residues such 
as MAP kinase phosphatase 7 (MKP7) (Camps et al., 2000, Keyse, 2000, N. K. Tonks 
and Neel, 2001). MKP7 has been shown to suppress the activity of JNK (Masuda et 
al., 2001). In addition, protein phosphatase type 2C α (PP2Cα) has also been reported 
to dephosphorylates MAPKKs (MKK6 and MKK4) leading to the inhibition of JNK 
signalling (Takekawa et al., 1998). However, one of DSPs, Jnk Stimulatory 
Phosphatase 1 (JSP-1) activates JNK by enhancing the activity of JNK upstream 
protein, MKK4 (Shen et al., 2001). 
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Figure 1.6. Schematic representation of the JNK pathway. Grb2/Sos1 complex binds to 
phosphorylated Tyr716 residue on PDGFbR in order to activate Ras by converting Ras from 
inactive GDP-bound form to its active GTP-bound form. This leads to initiating signal 
transduction cascade including Rac, MLKs, MKK4 and MKK7. MKK4 phosphorylates 
Tyr185 whereas MKK7 phosphorylates Thr183 JNK full activation. Upon activation, JNK can 
phosphorylate its downstream effector such as c-Jun leading to a transcriptional affect.  
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1.3. Protein Tyrosine Phosphatases 
1.3.1. Introduction 
Tyrosine phosphorylation is a fundamental mechanism in signal transduction for 
enzyme activity and play a crucial role for regulation a wide range of physiological 
processes in health and disease (T. Hunter, 1987, Mustelin et al., 2002). There is a 
large volume of published studies describing the role of protein tyrosine phosphatases 
(PTPs) in regulating cellular functions including cell migration, proliferation and 
differentiation. Protein tyrosine phosphatases are classified into four major classes 
(Figure 1.7); class I PTPs which include classical PTPs and dual specificity 
phosphatases (DSPs) (Alonso et al., 2004).  
Classical PTPs are strictly tyrosine specific (Andersen et al., 2004) whereas DSPs are 
more diverse group and able to dephosphorylate serine, threonine, inositol 
phospholipids or mRNA (Alonso et al., 2004, Ostman et al., 2006). Class II PTP 
contains a single PTP called low molecular weight PTP (LM-PTP) which is tyrosine 
specific (X. D. Su et al., 1994, N. K. Tonks, 2006a).	Class III PTPs which include 
CDC25 family members (CDC25A, CDC25B, CDC25C) PTPs and are 
tyrosine/threonine-specific phosphatases mainly involved in regulation of cell cycle 
(Fauman et al., 1998, McCain et al., 2002). Class IV PTPs include eyes absent 
homologue (EYA) proteins and act as serine/tyrosine affinity (Julien et al., 2011, 
Rayapureddi et al., 2003, Tootle et al., 2003). 
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Figure 1.7. The classification of PTPs with their substrate specificity. Adapted from 
(Alonso et al., 2004). 
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Classical PTPs are divided into two subfamilies, receptor-like PTPs (RPTPs), 
including CD45, LAR, PTPα and non-receptor PTPs (NPTPs) such as SHP-1, TC-PTP 
(Andersen et al., 2001, N. K. Tonks, 2006a, N. K. Tonks and Neel, 2001). Structurally, 
RPTPs are composed of extracellular domains that have immunoglobulin and 
fibronectin type III domains, which are involved in cell-cell interaction. In addition, 
most RPTPs have intracellular regions with phosphatase activity domains (D1) and 
regulatory domains (D2) (N. K. Tonks, 2006a).  
The majority of the PTPs, in particular the classical PTPs use the same mechanism to 
regulate the catalytic activity. PTPs contain a nucleophilic cysteinyl residue, which 
has been shown to recognize the phosphate group of the target substrates for 
dephosphorylation (Shi, 2009). PTPs either receptor-like or non-receptor have been 
shown to play a key role in regulating a wide range of signal transduction proteins 
(Gurzov et al., 2015). 
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1.3.2. LAR Protein Tyrosine Phosphatase 
1.3.2.1. Structure 
Leukocyte common antigen-related (LAR), also known as receptor type protein 
tyrosine phosphatase F (PTPRF), is a receptor-like protein tyrosine phosphatase 
(RPTP). LAR is composed of an extracellular region containing three N-terminal 
immunoglobulin-like domains and eight fibronectin type III repeats (FnIII) (Serra-
Pages et al., 1994). The intracellular part of LAR is composed of a proximal 
phosphatase domain called D1 and a distal phosphatase domain called D2 (Figure 1.8) 
(Nam et al., 1999, Streuli et al., 1988). D1 has a phosphatase activity while D2 shows 
a regulatory function and gives the protein substrate specificity (Streuli et al., 1990, 
Tsujikawa et al., 2001).  
Crystal structure analysis showed that D1 and D2 are very similar differing by only 
two amino acids in D2 domain (Leu-1644 and Glu-1779) (Nam et al., 1999). 
Interestingly, the substitution of Leu-1644 to Tyr and Glu-1779 to Asp in D2 convert 
the domain from regulatory to fully active as D1 (Nam et al., 1999). On the other hand, 
FnIII domains are composed of eight fibronectins type III repeats which are 
approximately 90 amino acids long and have suggested to be involved in cell adhesion 
(Beltran and Bixby, 2003). It has been shown that laminin-nidogen complex bind to 
FnIII domain 5 on LAR and act as a ligand (O'Grady et al., 1998). However, the 
physiological function for this binding has not been studied.  
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Figure 1.8. Schematic structure of LAR. Ig, immunoglobulin-like domain; FNIII, 
fibronectin type III repeat domain; TM, transmembrane; D1, phosphatase domain 1; D2, 
phosphatase domain 2. 
 
1.3.2.2. Mechanism  
Most PTPs are cysteine-based and share a common motif sequence (H/V)CX5R(S/T) 
to form a phosphate binding loop (P-loop) where the catalytic reaction occurs (Cirri et 
al., 1993, Kolmodin and Aqvist, 2001). The hydrolysis reaction utilises two steps 
(Figure 1.9). First, nucleophilic attack by cysteine in the P-loop on the phosphorus 
atom of the substrate in order to break the phosphorus–oxygen bond. Simultaneously, 
the catalytic aspartate in the WPD (Trp-Pro-Asp) loop works as a general acid to 
donate a proton to the oxygen leaving group, resulting the formation of phospho-
cysteine and releasing of dephosphorylated substrate (K. L. Guan and Dixon, 1991, 
Kolmodin and Aqvist, 2001, Pannifer et al., 1998). The second step is initiated by 
hydrolysis of the phospho-cysteine intermediate with the assistance of the aspartate in 
the WPD loop yielding free phosphate (Brandao et al., 2012, Kolmodin and Aqvist, 
2001, S. Zhao et al., 2015a).  
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Figure 1.9. Schematic diagram representing the mechanism of action of PTPs. See LAR 
mechanism 2.2.2 section for more details (S. Zhao et al., 2015a). 
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1.3.2.3. Function 
A number of studies have found that LAR plays an important role in regulating cell 
signalling and contributing to cellular functions such as neuronal growth and neuronal 
regeneration (Sethi et al., 2010). On the other hand, several phenotypic disorders have 
been recognized in LAR-deficient mice including defective development of mammary 
gland, neuron degeneration, axon guidance defects, reduction in the rate of hepatic 
glucose production, diabetes and cancer (Andersen et al., 2001, Bera et al., 2014, Du 
et al., 2013, Soulieres et al., 2015, Van Lieshout et al., 2001, Whitmore et al., 2012, 
Zabolotny et al., 2001). Mouse embryos lacking LAR (Ptprf) and RPTPσ (Ptprs) 
showed defects in embryos development such as small lower jaw, cleft palate and 
microglossia (small and deep tongue phenotype). This was due to the hyperactivation 
of Smad signalling and the downregulation of Wnt signalling in embryos and cells 
lacking LAR family phosphatase genes (Stewart et al., 2013).  
Recently, quantitative proteomics study revealed that LAR is significantly expressed 
in lung cancer demonstrating LAR as potential biomarker for nonsmall cell lung 
cancer (P. J. Liu et al., 2015). Tumor promoter TPA induces cleavage of LAR into the 
extracellular subunit (E-subunit) and phosphatase subunit (P-subunit) in response to 
EGF (Ruhe et al., 2006). TPA also promotes the degradation of P-subunit and this 
proteolytic processes could be mediated by ADAM-17 (a disintegrin and 
metalloproteinase) (Ruhe et al., 2006). MicroRNA miR-24 increases EGFR 
phosphorylation and activation in breast carcinoma through the suppression of LAR 
expression resulting in promotion of tumor growth, cell invasion and metastasis (Du 
et al., 2013). Many studies in Drosophila demonstrated that Abl as substrate for 
Drosophila LAR (DLAR) and mediate several cellular functions (M. J. Chagnon et 
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al., 2004b). Enabled protein (Ena), a substrate of Abl, is active in its unphosphorylated 
state. Abl phosphorylates and inactivates Ena while LAR dephosphorylates Ena for 
activation demonstrating that Ena connecting Abl and LAR to control and maintain 
axon guidance (Sirvent et al., 2008, Wills et al., 1999). 
In contrast to receptor tyrosine kinases which are activated by dimerization, receptor-
like phosphatases (RPTPs) are negatively regulated via ligand-induced dimerization 
such as RPTPα, RPTPβ and CD45 (Majeti et al., 1998, N. K. Tonks, 2006a). This 
occurs due to interaction of one D1 domain with the active site of the adjacent D1 
domain in the dimer leading to deactivation of both proteins (Bilwes et al., 1996, 
Blanchetot and den Hertog, 2000, Majeti et al., 1998, N. K. Tonks, 2006a). 
Homodimerization can also occur in the majority of RPTPs via the transmembrane 
domains (Chin et al., 2005). Later on researchers indicated that the induction of H2O2 
can causes conformational changes in D1 and D2 of the cytoplasmic domains of LAR 
leading to promote the dimerization (Groen et al., 2008). 
Data from several sources have identified a number of ligands, which bind to 
extracellular domains of LAR. For instance, laminin–nidogen complex has shown to 
bind to the fibronectin type III position 5 (O'Grady et al., 1998). Fox and Zinn 
described the heparan sulfate proteoglycan syndecan (Sdc) as a new ligand for 
Drosophila LAR (DLAR) and it has shown positively regulates DLAR signalling (Fox 
and Zinn, 2005). Loss of Sdc leads to impaired growth and axon guidance suggesting 
that Sdc positively regulates LAR in vivo. LARFN5C has also been identified as a 
ligand that associates with LAR to initiate cellular signalling pathways in neurons (T. 
Yang et al., 2003). 
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In 1995, Serra-Pages and co-workers demonstrated that LAR can binds to LAR-
interacting protein 1 which now called Liprin 1 and localise to focal adhesion (Serra-
Pages et al., 1995). Later on, researchers have found that Trio, which is a multidomain 
protein with two GEF domains and one kinase domain, binds with LAR cytoplasmic 
domains proposing a signalling pathway links LAR and Trio in regulation of cell 
adhesion and migration (Debant et al., 1996). In addition, LAR has been found 
associated with cadherin-catenin complex and mediates the dephosphorylation of 
tyrosine residues on b-catenin (Kypta et al., 1996). Up to now, however, the role of 
LAR in cell adhesion and mechanism of action remain unclear.  
 
 
 
1.3.2.4. Role of LAR in Regulation of Receptor Tyrosine 
Kinases 
 
Many protein tyrosine kinases have been identified as substrates for LAR such as the 
insulin receptor, EGF receptor and HGF receptor (Ahmad and Goldstein, 1997, Kulas 
et al., 1996). LAR associates with the insulin receptor and decreases the 
autophosphorylation of the receptor suggesting LAR as a pharmacological target for 
the treatment of diabetes and obesity (M. J. Chagnon et al., 2004b, Goldstein, 2002, 
Kulas et al., 1995, Tsujikawa et al., 2001). A method called “PTPs substrate trapping 
mutants” have been commonly used to identified physiological substrates. These 
mutations and name ‘Substrate-trap’ were firstly discovered by Tonks lab (Flint et al., 
1997, Jia et al., 1995, Sun et al., 1993). To this end, when the PTP binds to 
phosphorylated tyrosine residue on the substrate for dephosphorylation, substrate can 
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trap in the catalytic pocket of the protein tyrosine phosphatase (Blanchetot et al., 2005, 
Flint et al., 1997).  
LAR substrate trapping mutants can be generated by substitution of cysteine 1548 in 
the active site with serine (LAR C/S) or by substitution of aspartic acid 1516 with 
alanine (LAR D/A) (W. J. Wang et al., 2007). By using this approach, a number of 
substrates have been identified for LAR. For example, LAR can interact and 
dephosphorylate insulin receptor suggesting that insulin receptor is a substrate for 
LAR (Tsujikawa et al., 2001). Ephrin type-A receptor 2 (EphA2) has also been shown 
as LAR substrate by using LAR-substrate trapping mutants. LAR binds directly to 
EphA2 and dephosphorylates Tyr930 on the receptor where Nck1 is bound leading to 
reducing EphA2 mediated cell migration  (H. Lee and Bennett, 2013).  
Depletion of LAR in rat hepatoma cell line resulted in increases the 
autophosphorylation level of hepatocyte growth factor (HGF) demonstrating that LAR 
negatively regulates HGF signalling (Kulas et al., 1996). LAR can also bind with and 
deactivates the proto-oncogenic RET receptor by reducing the tyrosine 
autophosphorylation level (Qiao et al., 2001). In contrast, the autophosphorylation of 
FGF and EGF not affected by LAR, instead, LAR can mediate the dephosphorylation 
and deactivation of adaptor proteins downstream FGFR and EGFR such as Fibroblast 
growth factor receptor substrate 2 (FRS2) and Breast cancer anti-estrogen resistance 
protein 1 (p130CAS) (X. Wang et al., 2000). Interestingly, LAR can inhibit FGF-
induced MAPK signalling, while the activation of MAPK signalling induced by EGF 
is not affected indicating the specificity of LAR function in response to different 
growth factors (X. Wang et al., 2000). LAR can enhance PDGFβR activation and 
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signalling by supresses c-Abl activity (Zheng et al., 2011). However, the mechanism 
behind this inhibition is not understood. 
 
1.4. Quantitative phosphoproteomics in studying cell signalling 
 
Phosphorylation is one of the most common post-translational modifications that 
occurs in the cell and affects protein activity which in turn control the majority of 
cellular processes including cell proliferation, growth, survival and differentiation (T. 
Pawson, 2004). Protein phosphorylation also regulates protein-protein interactions and 
initiates signal transduction by add or remove phosphate groups, therefore switching 
“on” or “off” protein activity (T. Pawson and Scott, 1997). This function is modulated 
by kinases and phosphatases (Bauman and Scott, 2002). Over 400,000 
phosphorylation site on >50,000 proteins for all phosphorylation types (Ser, Thr and 
Tyr) now list on the Phosphosite database (http://www.phosphosite.org) and this 
number is increasing because each phosphoproteomic large scale study identifies more 
novel phosphosites (Hornbeck et al., 2012). 
Many of the biochemical methods have been widely used to study protein activity or 
protein-protein interaction on an individual basis. However, this kind of approaches 
can be arduous and time-consuming especially if the goal is to identified novel 
regulators or therapeutic targets. Therefore, mass spectrometry-based quantitative 
phosphoproteomics technique can be used for high-throughput experiments in order 
to monitoring the differential phosphorylation events and to study signalling pathways 
within the cell (Gygi et al., 1999, Harsha et al., 2008, Humphrey et al., 2015, Rigbolt 
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et al., 2011a, Rikova et al., 2007). The biochemical methods can then be used for the 
protein of interest for the validation. 
One of the most commonly use technique for the quantitative phosphoproteomics is 
Stable isotope labelling by amino acids in cell culture (SILAC) (S. E. Ong et al., 2002). 
To this end, cells can be grown in culture medium that contains normal amino acid or 
medium where the normal amino acids, arginine and lysine are replaced with medium 
(13C6 L-Arginine; 4,4,5,5-D4 L-Lysine) or heavy (13C6 15N4 L-Arginine; 13C6 15N2 L-
Lysine) amino acid (Mann, 2006). To ensure that all amino acids are incorporated into 
the proteome, cells need to be grown in SILAC medium at least five doubling times 
(S. E. Ong and Mann, 2006). The incorporation of these amino acids into the proteome 
leading to known mass shift in the peptide compared with peptide that has light amino 
acid (Shao-En Ong and Mann, 2007). SILAC-based proteomics or phosphoproteomics 
have been widely used in cell biology field and several interesting findings have been 
obtained by using this approach (Humphrey et al., 2015, Humphrey et al., 2013, Leroy 
et al., 2009, Oppermann et al., 2009, Wilhelm et al., 2014a).  
In this thesis, global SILAC-based phosphoproteomics was used to gain insight into 
the signal transduction pathways regulated by platelet-derived growth factor (PDGF) 
and Leukocyte common antigen-related protein (LAR).  
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Thesis Aims 
 
 
1. To further investigate the tyrosine phosphorylation of PDGFβR in two 
cell lines WT and LAR∆P MEFs in response to PDGF-BB stimulation. 
2. Global SILAC-based mass spectrometry phosphoproteomics study to 
analyse differential phosphorylation in WT and LAR∆P MEFs. 
3. To test if the deletion of LAR phosphatase domains affects the PDGFβR 
downstream signalling including Akt, MAPK, JNK and mTOR signalling 
pathways. 
4. To test if deletion of LAR phosphatase domains affects the cell adhesion 
to ECM. 
5. To investigate the regulation of focal adhesions by LAR. 
6. Global SILAC-based mass spectrometry phosphoproteomics study to 
identify novel PDGF-regulated proteins. 
7. To investigate the regulation of PDGFβR downstream proteins by 
GRK2. 
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CHAPTER 2 
MATERIALS AND METHODS 
	
	
2.1. Antibodies, reagents and plasmid constructs 
The primary antibodies used in this project are listed in Table 2.1. Secondary goat 
anti-mouse and goat anti-rabbit IgG IRDye conjugated antibodies were purchased 
from Licor Biosciences. Rabbit polyclonal antibody against the C-terminus of the 
PDGF β-receptor was a kind gift from Prof. Carl-Henrik Heldin (Ludwig Cancer 
Research, Uppsala, Sweden). Rabbit polyclonal antibody against Alix has been 
previously described (Karlsson et al., 2006, Lennartsson et al., 2006). Phalloidin Alexa 
594 was from Invitrogen. Recombinant human PDGF-BB was purchased from Cell 
Signalling Technologies. The inhibitors, AG957 (c-Abl inhibitor) was purchased from 
Sigma-Aldrich; RO-3306 (CDK1 inhibitor) was from Millipore; InSolution Akt 
Inhibitor VIII, Okadaic Acid and SP600125 (JNK inhibitor) were purchased from 
Calbiochem. A plasmid expressing PDGFbR was a kind gift from Dr Neil Freedman 
(Duke University School of Medicine, Durham, USA). Plasmids expressing NHERF2 
(plasmid #47801), cdc2-AF (plasmid #39872), cdc2 (Plasmid #1888), c-Abl (plasmid 
#52684) were purchased from Addgene. Full-length FLAG-tagged wild-type LAR 
(WT) and substrate-trapping mutants, CS (Cys1548 in the D1 domain was replaced 
with Ser1548) and DA (Asp1516 in the D1 domain was replaced by Ala1516), were 
kindly provided by Ruey-Hwa Chen (National Taiwan University, Taipei, Taiwan). 
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Table 2.1. Primary antibodies used in the study. IF: immunofluorescence, WB: Western 
blotting, IP: immunoprecipitation.  
 
No. Antibody Supplier Dilution
1 LAR  NeuroMab 10 µg/mL (WB)
2 c-Abl Cell Signaling Technology  1:1000 (WB)-1:200 (IP)
3 NHERF-1 Cell Signaling Technology  1:1000 (WB)-1:200 (IP)
4 NHERF-2 Santa Cruz Biotechnology  1:2000 (WB)- 2µg/ml (IP)
5 SAPK/JNK Cell Signaling Technology  1:1000 (WB)
6 pSAPK/JNK (Thr183/Tyr185) Cell Signaling Technology  1:1000 (WB)-1:200 (IP)
7 Src Cell Signaling Technology  1:1000 (WB)-1:100 (IP) (IF)
8 pSrc (Tyr416) Cell Signaling Technology  1:1000 (WB)
9 p38 MAPK Cell Signaling Technology  1:1000 (WB)-1:100 (IP)
10 pp38 MAPK (Thr180/Tyr182) Cell Signaling Technology  1:1000 (WB)-1:50 (IP)
11 GRK2 Santa Cruz Biotechnology  1:1000 (WB)-2µg/500µg of WCL (IP)
12 GRK5 Santa Cruz Biotechnology  1:1000 (WB)-2µg/500µg of WCL (IP)
13 β-Actin Sigma-Aldrich 0.5µg/ml (WB)
14 c-Jun Cell Signaling Technology  1:1000 (WB)-1:50 (IP)
15 pc-Jun (Ser63) Cell Signaling Technology  1:1000 (WB)-1:50 (IP)
16 MKK7 Cell Signaling Technology  1:1000 (WB)-1:50 (IP)
17 pMKK7 (Ser271/Thr275) Cell Signaling Technology  1:1000 (WB)
18 PKCδ Cell Signaling Technology  1:1000 (WB)-1:25 (IP)
19 SEK/MKK4 Cell Signaling Technology  1:1000 (WB)-1:50 (IP)
20 pSEK/MKK4 (Thr261) Cell Signaling Technology  1:1000 (WB)
21 Akt Cell Signaling Technology  1:1000 (WB)
22 pAkt (Thr308) Cell Signaling Technology  1:1000 (WB)-1:100 (IP)
24 FAK BD Biosciences  1:1000 (WB)
25 pFAK (Tyr407) Santa Cruz Biotechnology  1:1000 (WB)-2µg/500µg of WCL (IP)
26 pFAK (Tyr397) BD Biosciences  1:1000 (WB)-1:100 (IF)
27 Erk1/2 Santa Cruz Biotechnology  1:1000 (WB)-2µg/500µg of WCL (IP)
28 pErk (Thr202/Tyr204) Santa Cruz Biotechnology  1:1000 (WB)-1:50 (IP)
29 pATF-2 (Thr69/71) Cell Signaling Technology  1:1000 (WB)
30 mTOR Cell Signaling Technology  1:1000 (WB)
31 pmTOR (Ser2448) Cell Signaling Technology  1:1000 (WB)
32 pp70 S6 Kinase (Thr389) Cell Signaling Technology  1:1000 (WB)
33 Paxillin Cell Signaling Technology  1:1000 (WB)
34 pPaxillin (Tyr118) Cell Signaling Technology  1:1000 (WB)-1:50 (IF)
35 CDK1 Thermo Fisher 1-2 µg/ml (WB)-2 µg/ml (IP)-1:25 (IF)
36 pCDK1 (Thr161) Cell Signaling Technology  1:1000 (WB)
37 cyclin B1 Santa Cruz Biotechnology  1:1000 (WB)-2µg/500µg of WCL (IP)
38 p-Tyr Antibody (PY99) Santa Cruz Biotechnology  1:1000 (WB)-2µg/500µg of WCL (IP)
39 Rac1 BD Biosciences  1:1000 (WB)
40 RhoA Santa Cruz Biotechnology  1:1000 (WB)-2µg/500µg of WCL (IP)
41 FLAG M2 Sigma-Aldrich 10 mg/mL (WB)-20 mg/mL (IF)
42 eps8 Santa Cruz Biotechnology  1:1000 (WB)-2µg/500µg of WCL (IP)
43 CRMP2 Cell Signaling Technology  1:1000 (WB)-1:50 (IP)
44 pCRMP2 (Thr514) Cell Signaling Technology  1:1000 (WB)
45 pThr antibody Cell Signaling Technology  1:1000 (WB)-1:50 (IP)
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2.2. Cell Culture  
Mouse embryonic fibroblasts (MEFs) from mice where the LAR phosphatase domains 
had been deleted (LARΔP) and wild-type (WT). MEFs are isolated from embryos 
(single clone) and allowed to grow in culture medium as described in  (Schaapveld et 
al., 1997). MEFs and Human embryonic kidney (HEK 293T)	were grown in DMEM 
supplemented with 10% foetal bovine serum (FBS), 100 U/mL Penicillin, 10 mg/mL 
Streptomycin, and 250 µg/mL Amphotericin B. 
 
2.3. Cell stimulation, cell lysis, immunoprecipitation and 
immunoblotting 
The cells were counted and seeded into the indicated plate for each experiment. Cells 
were then grown in DMEM medium with FBS (complete medium) to approximately 
80% confluency and starved for 16 hours in DMEM medium without FBS (starvation 
medium). Where applicable, cells were incubated with 10 µM c-Abl inhibitor (AG957) 
for 2 hours, or 10 µM CDK1 inhibitor (RO-3306) for 1 hour, or 10 µM InSolution Akt 
Inhibitor VIII overnight, or 20 µM JNK inhibitor (SP600125) for 1 hour, or 0.01 µM, 
1 µM, 1.5 µM okadaic acid for 30 min.  
Where appropriate, the starvation media was removed and the cells were stimulated 
with 20 ng/mL PDGF-BB for the indicated times at 37°C. Cells were then placed on 
ice, rinsed twice with cold phosphate buffered saline PBS (135 mM NaCl, 1.5 mM 
KH2PO4, 2.7 mM KCl, and 8 mM K2HPO4, pH 7.4), and then lysed in lysis buffer (20 
mM Tris–HCl, pH 7.5, 0.5% Triton X-100, 0.5% deoxycholate, 150 mM NaCl, 10 
mM EDTA, 0.5 mM Na3VO4, and 1% Trasylol) for 15 minutes on ice. The lysed cells 
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were scraped down, collected by centrifugation (15000g/ 15 minutes), and the 
supernatant transferred to an eppendorf tube.  
The protein concentration in each sample was determined using the Coomassie blue 
protein assay (Thermo Fisher Scientific) as described in the manufacturer's protocol. 
Immunoprecipitation of PDGFβR and the indicated proteins was carried out using 
Dynabeads protein G (Thermo Fisher Scientific) or Anti-Flag beads (Sigma) according 
to manufacturer's protocol. Equal volumes of 2X sample buffer (1.0M Tris-HCl pH 
8.8, 0.5% Bromophenol blue, 43.5% glycerol, 10% SDS, 1.3% β-mercaptoethanol) 
was added to the beads or whole cell lysate (WCL), boiled at 95 C° for 5 minutes. 
Samples from immunoprecipitation or WCL were loaded into SDS-PAGE gel and then 
transferred to Nitrocellulose membranes using Trans-Blot Turbo Transfer System 
(BIO-RAD).  
The membranes were blocked with 5% Bovine Serum Albumin BSA (Sigma Aldrich) 
at room temperature for one hour on the shaker. The membranes were then put into 
primary antibody solution (TBS-T: 1M Tris pH 7.5, 5M NaCl) containing 5% BSA 
and incubated at 4°C overnight on rotation. The membranes were then washed 3 times 
for 10 minutes with TBS-T and the secondary antibody solution in TBS-T was added 
at room temperature for 1 hour. The membranes were washed a further 3 times in TBS-
T prior to visualisation using the Odyssey Infrared Imaging System (LI-COR 
Biosciences). 
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2.4. Adhesion assay 
96-well plates were coated with serially diluted fibronectin (10 µg/mL to 0.009 µg/mL) 
in starvation medium overnight in 4 ˚C. The next day, the plates were washed three 
times with PBS and coated with 0.1% BSA, followed by incubation for 1 hour at 37 
C°. 50,000 cells were added to each well and incubated for 30 minutes at 37 C°. Plates 
were gently flicked off to discard cells that did not adhere on fibronectin and washed 
three times with PBS. 5 mg/mL of Thiazolyl Blue tetrazolium bromide (MTT) was 
added to each well and plates were incubated for 1 hour at 37 C° followed by addition 
of 100 µL of isopropanol. Plates were incubated for 15 minutes at room temperature 
with gentle shaking and the number of adherent cells were calculated by measuring 
absorbance at 570 nm. 
 
2.5. Immunofluorescence 
WT and LARΔP MEFs cells were seeded on coverslips and incubated at 37 C° 
overnight. The following day, cells were starved overnight. Where indicated, seeded 
cells were incubated with either 10 µM RO-3306 for one hour, 10 µM InSolution Akt 
Inhibitor VIII or DMSO overnight. Cells were stimulated with 20 ng/mL PDGF-BB 
for 15 minutes and incubated on ice for 5 minutes to terminate the stimulation. Cells 
were washed three times with PBS and fixed in 4 % paraformaldehyde for 10 minutes, 
washed with PBS three times and then permeabilized in ice cold 0.2 % Triton-X-100 
for 3 minutes. Cells were washes three times with PBS and blocked using 5% BSA in 
PBS at 37 C° for 1 hour and cells washed once with PBS and incubated with primary 
antibodies and Phalloidin Alexa 594 for 1 hour.  Cells were then washed with PBS and 
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incubated with appropriate secondary antibodies. Cells were visualized using 
confocal/ TIRF Nikon A1R with NIS-Elements Software and images were quantified 
using ImageJ 1.48. 
 
2.6. Quantitative phosphoproteomics study 
2.6.1. Cell culture 
For Stable Isotope Labelling of amino acids in Cell culture (SILAC) labelling, WT 
and LARΔP cells were cultured in SILAC DMEM (Thermo Fisher Scientific) 
supplemented with either “light” isotopically normal L-Lysine (Cat# L8662) and L-
Arginine (Cat# A8094) (R0K0) (Sigma), “medium” 13C6 L-Arginine (Cat# CLM-
2265-H) and 4,4,5,5-D4 L-Lysine (Cat# DLM-2640) (R6K4), or “heavy” 13C6 15N4 L-
Arginine (Cat# CNLM-539-H) and 13C6 15N2 L-Lysine (Cat# CNLM-291) (R10K8) 
(Goss Scientific), with 0.5 mg/mL proline (Sigma, Cat# P5607), 0.1mg/mL 
streptomycin, 100 U/mL penicillin, 250 µg/mL amphotericin B and 10% v/v dialysed 
fetal bovine serum (Labtech International) (Figure 2.1). 
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2.6.2. Tryptic digestion 
15 mg of light, medium and heavy lysates were pooled prior to trypsin digestion. 
Ammonium bicarbonate was added to give a final concentration of 50 mM. Proteins 
were then reduced with 8 mM Dithiothreitol (DTT) and incubated at 56 C° for 45 
minutes. Samples were alkylated with 20 mM Iodoacetamide in 50 mM Ammonium 
bicarbonate and incubated in dark for 45 minutes and then digested with trypsin Gold 
(Promega) (1 µg of enzyme/ 100 µg of protein) at 37 C° overnight. Digested samples 
were acidified by addition of 0.5% Trifluoroacetic acid (TFA).  
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Figure 2.1. Schematic overview of experimental design, phosphopeptide purification, 
and proteome analysis. (+) with PDGF-BB, (-) without PDGF-BB. 
 
WT LARΔP
Light Medium Heavy
+ -
+
Light Medium Heavy
Trypsin digestion Run SDS-PAGE gel
5 10 15 20 25 30 35 40 45 50 55 600
200
400
600
800
elution volume (mL)
Ab
so
rba
nc
e (
mA
U)
SCX fractionation
P
P
P
P
P
P
PP
PP
Enrichment of 
phosphopeptides
Mass spectrometry (Orbitrap Elite)
MaxQuant
In-gel digestion
Phosphoproteome Proteome
-
+
+Expt. 1
Expt. 2
Expt. 3
Expt. 4
Expt. 5
+-+
+-+
--+
Identification and quantification
46	
	
2.6.3. Desalting using Sep-Pak  
Peptides were desalted using SEP-PAK C18 Cartridges (Waters) according to 
manufacturer’s instructions. Briefly, each cartridge was washed with 100% 
Acetonitrile (ACN), conditioned with 50% ACN, 0.5% acetic acid, and equilibrated in 
0.1% TFA. The sample was loaded in 0.1% TFA. The cartridge was then washed with 
0.5% acetic acid, and the sample eluted in 50% ACN, 0.5% acetic acid. The desalted 
samples were then dried using vacuum centrifugation.  
 
2.6.4. Strong Cation Exchange (SCX) chromatography 
Desalted and dried peptides were resuspended in 1 mL mobile phase A (10 mM 
KH3PO4, 20 % acetonitrile, pH 3) and loaded onto a SCX Large (100×4.6 mm 
polysulfoethyl, 5 µm particle size, 200 nm pore size, PolyLC) column. Peptides were 
separated using a gradient elution profile that started with 100% mobile phase A, 
increased from 0 to 50% mobile phase B (10 mM KH3PO4, 20% acetonitrile, 500 mM 
KCl, pH 3) over 60 min, increased to 100% mobile phase B over 10 min, and then 
returned to 100% A. The column flow rate was 1 mL/ minute. 
 
2.6.5. Desalting and concentrating peptides using Macrotrap 
Fractions collected from the SCX column were combined to give 20 fractions for each 
experiment. Samples were dried and desalted using a C8 Macrotrap cartridge with 50 
µL bed volume (Michrom BioResources) according to manufacturer’s protocol. 
Briefly, the cartridge was cleaned/ regenerated with 10 volumes 70% formic acid/ 30% 
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isopropanol and washed with 5-10 volume 90% ACN/ 0.1% TFA. It was then 
equilibrated in 5-10 volume 2% ACN, 0.1% TFA and the samples were loaded in 1mL 
2%, 0.1 TFA. Peptides were washed with 5 volumes 2% ACN, 0.1% TFA to remove 
the salts and eluted with 300 µL of 90% ACN, 0.1% TFA. Peptides were dried using 
vacuum centrifugation. 
 
2.6.6. Enrichment of phosphopeptides 
Phosphopeptides were enriched using TiO2 tips (TitansphereTM Phos-TiO kit, GL 
Sciences). Tips were washed in buffer A (0.5% TFA, 80% ACN) and equilibrated in 
buffer B (0.38% TFA, 60% ACN, 25% lactic acid). Phosphopeptides were 
resuspended in buffer B and loaded onto the tips, washed once in buffer B and twice 
in buffer A before being eluted sequentially in 5% ammonia solution followed by 5% 
pyrrolidine. Phosphopeptide-enriched samples were desalted using ZipTips 
(Millipore) according to manufacturer’s protocol. Peptides were eluted in 50% ACN, 
0.1% TFA, dried and resuspended in 0.1% formic acid. 
 
2.6.7. In-gel Trypsin Digestion 
For the proteome study, in-gel trypsin digestion was done as previously described 
(Cunningham et al., 2010, Shevchenko et al., 2006). Briefly, bands were excised from 
the gel and cut into small pieces, before being destained in 30% acetonitrile for 15 min 
incubation with agitation. Then, 50% acetonitrile, 25 mM ammonium bicarbonate was 
added for 15 min.  The gel pieces were dehydrated in a vacuum centrifuge for 5 min 
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followed by rehydration in 10 mM DTT, 25 mM ammonium bicarbonate at 56 C° for 
45 min. Gels were then alkylated with 55 mM iodoacetamide, 25 mM ammonium 
bicarbonate at room temperature, in the dark for 45 min. The gel pieces were then 
washed with 25 mM ammonium bicarbonate once for 10 min and 50% acetonitrile, 25 
mM ammonium bicarbonate twice for 5 min. Trypsin was first resuspended in 20 µL 
of 50 mM acetic acid and then diluted in 25 mM ammonium bicarbonate to give a final 
concentration of 12.5 ng/µL. Trypsin was added to gel pieces and incubated overnight 
at 37 C°. Samples were concentrated using vacuum centrifugation and resuspended in 
10 µL 0.1% formic acid. 
 
 
2.6.8. Mass spectrometry (work performed by The Proteomics and 
Metabolomics Facility, University of Birmingham) 
All resulting peptide mixtures were analysed in duplicate by liquid chromatography 
tandem mass spectrometry (LC-MS/MS). On-line liquid chromatography was 
performed by use of a Dionex Ultimate 3000 LC system (Thermo Fisher Scientific). 
Peptides were loaded onto an Acclaim PepMap 100 C18 resolving column (15 cm 
length; 75 µm internal diameter; LC Packings, USA) and separated over a 40 min 
gradient from 3.2 % to 44 % acetonitrile (Baker, Holland). Peptides were eluted 
directly (350 nL/min) via a Triversa nanospray source (Advion Biosciences, NY, 
USA) into a LTQ Orbitrap Elite mass spectrometer (Thermo Fisher Scientific). The 
mass spectrometer alternated between a full FT-MS scan (m/z 380-1600) and 
subsequent CID MS/MS scans of the twenty most abundant ions. Survey scans were 
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acquired in the Orbitrap cell with a resolution of 60,000 at m/z 200. Precursor ions 
were isolated and subjected to CID in the linear ion trap. Isolation width was 2 Th. 
Only multiply charged precursor ions were selected for MS/MS. CID was performed 
with helium gas at normalized collision energy of 35 %. Precursor ions were activated 
for 10 ms. Data acquisition was controlled by Xcalibur 3.0.63 software. 
 
2.6.9. Peptide identification using MaxQuant/ Andromeda 
Mass spectra were processed using the MaxQuant software (version 1.5.3.8) (Cox and 
Mann, 2008). Data were searched, using the Andromeda search engine within 
MaxQuant (Cox et al., 2011),  against the mouse Swiss-Prot database (downloaded 
6.10.15). The mouse database contained 16,719 reviewed protein entries. The search 
parameters were: minimum peptide length 7, peptide tolerance 20 ppm (first search) 
and 6 ppm (second search), mass tolerance 0.5 Da, cleavage enzyme trypsin/P, and 2 
missed cleavages were allowed. Carbamidomethyl (C) was set as a fixed modification. 
Oxidation (M), acetylation (Protein N-term), and phospho (STY) were set as variable 
modifications. The appropriate SILAC labels were selected and the maximum labelled 
amino acids was set to 3. All experiments were filtered to have a peptide and protein 
false-discovery rate (FDR) below 1 %. Within the MaxQuant output, phosphorylation 
sites were considered to be localised correctly if the localisation probability was at 
least 0.75 (75 %) and the score difference at least 5. Bioinformatics analysis was 
performed in the Perseus software environment, which is part of MaxQuant (Perseus 
version 1.5.0.15; www.perseus.framework.org). Significance testing was carried out 
using a Student’s t-test on log 2 transformed ratios and controlled with a Benjamini-
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Hochberg FDR threshold of 0.05. Peptides quantified in three or more experimental 
repeats were deemed significantly changed and regulated by LAR phosphatase activity 
if they had a p-value of < 0.05 and a ratio of < 0.667 or > 1.5 (at least a 1.5-fold change 
in abundance). The mass spectrometry proteomics data, including the MaxQuant 
output, have been deposited to the Proteome Xchange (Vizcaino et al., 2013) 
Consortium via the PRIDE partner repository with the dataset identifier PXD002545. 
 
 
2.6.10. Cluster and Kinase motif analysis 
GProX software (Rigbolt et al., 2011b) was used to perform clustering of log2 
transformed ratios from MaxQuant output. Unsupervised fuzzy c-means clustering 
was used with an upper regulation threshold of 1 and a lower regulation threshold of -
1. Phosphopeptides containing well localised phosphosites were analysed using the 
Group-based Prediction System (GPS; version 2.1.2) (Xue et al., 2008) for kinase 
motifs in order to predict upstream kinases. To minimize false positives, the highest 
threshold was applied. Kinases upstream of the identified PDGF-regulated 
phosphopeptides were predicted using Kinase Enrichment Analysis (KEA) 
(Lachmann and Ma'ayan, 2009). 
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2.6.11. Functional enrichment analysis 
DAVID (Database for Annotation, Visualization and Integrated Discovery) (Huang da 
et al., 2009) was used to identify over-represented GO terms and KEGG pathways. 
The background list comprised of all the proteins identified across our experiments. 
The threshold count and EASE score were set to 2 and 0.05 respectively. REVIGO 
(Supek et al., 2011) was also used for identified and visualised over-presented GO 
terms. 
 
2.6.12. Protein-protein interaction network analysis 
Protein-protein interaction (PPI) network analyses were performed using Cytoscape 
(version 3.3.0) (Shannon et al., 2003) with GLay plugin for network clustering and 
structured visualization (G. Su et al., 2010) and BiNGO plugin to assess over-
representation of GO terms within the network (Maere et al., 2005). Indicated PPI 
networks were also built using interaction information obtained from a public database 
using the PSICQUIC client in Cytoscape (Aranda et al., 2011). 
 
2.6.13. Reprocessing proteomics public data and protein expression 
analysis 
Data from human proteome project (Wilhelm et al., 2014b) was reanalyzed using 
PRIDE Reshake function in PeptideShaker software (Vaudel et al., 2015). For the 
analysis of protein expression (protein abundance), the number of peptide spectrum 
matches (PSM) were normalized based on the total sum of all PSMs to be able to 
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compare protein abundances across multiple samples (Kuntumalla et al., 2009, 
Wilhelm et al., 2014b). Protein abundances were obtained by dividing normalized 
PSMs by its molecular weight. Protein abundance was also calculated by using the 
iBAQ option (intensity based absolute protein quantification) in MaxQuant 
(Schwanhausser et al., 2011). iBAQ is the summation of peptide intensities for the 
protein in a sample divided by the number of observable peptides. iBAQ values were 
then normalized and log10 transformed. 
 
2.7. RNA interference 
Cells were transfected with 80 pmol of ON-TARGET plus Mouse siRNA 
SMARTpool siRNA for LAR (CGAAUUACGUGGAUGAAGA; 
GCUUUGAGGUAAUUGAGUU; GGACUUCUGGCGCAUGUUA; 
GAAUAUGCUUUCCGUGUGU), GRK2 (GAUCCCUGCUGGAAGGUUU; 
GAUCUUUGACUCCUAUAUU; CCAGAUCUCUUCCAGCCAU; 
GCAAGUGUCUCCUGCUUAA), or CRMP2 (GUUGAGAAGAGGCGGGUUU; 
GUGCUCAGAUUGACGACAA; CGGCUGAAGUCAUCGCUCA; 
GGGAAUGACAUCCGCUGAU) (Dharmacon). Non-Targeting siRNA was used as 
a control for each preformed experiment. Lipofectamine RNAiMAX (Invitrogen, Life 
Technologies) was using as transfection reagent and the siRNA transfection was done 
for 48 hours according to the manufacturer's protocol. 
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2.8. Transformation and DNA transfection 
For the amplification of plasmids, 5 µL of each plasmid was mixed with 50 µL of 
either E. coli DH5α strain or MC1061/P3 strain and incubated on ice for 20 minutes. 
The mixture was heat shock in 42°C for 30-60 seconds followed by 3 min incubation 
on ice. The mixture was added to 950 µL of LB media (without antibiotics) and 
incubated for 45min in 37°C with shaking. 200 µL of the transformed cells was plated 
onto a 10 cm LB agar plate containing the appropriate antibiotic and incubated 
overnight at 37 C°. One colony was picked and added to 250 mL of LB medium with 
the appropriate antibiotic and incubated overnight at 37 C° with agitation. Plasmids 
were purified using the PureYield Plasmid Maxiprep System (Promega) according to 
manufacturer’s instructions. Cell lines were transiently transfected with the indicated 
constructs using Lipofectamine 2000 (Thermo Fisher Scientific) according to 
manufacturer’s protocol. 
	
 
2.9. Measurement of mitochondrial respiration 
The Seahorse XF24 (Seahorse Biosciences) was used to determine the mitochondrial 
respiration by measuring oxygen consumption rate and extracellular acidification rates 
as previously described (Rogers et al., 2011, Salabei et al., 2014). WT and LARDP 
cells were seeded to 40,000 cells/ well in XF24 cell culture plates and incubate in either 
complete or starvation media for 24 h prior to the assays. Oxygen consumption rate 
(OCR) was measured under basal state followed by the sequential injection of 
oligomycin (Oligo; 1 µM), carbonyl cyanide p-trifluoromethoxy-phenylhydrazone (FCCP; 1 
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µM), and Rotenone/ Antimycin A (0.5 µM). The assay was run in 3 technical replicates 
for each independent biological replicate (n = 3).	Cells were counted in each well 
following an assay to normalize OCR raw data.  
 
2.11. Scratch wound assay 
Cells were plated in 96-well cell culture plates and cultured to confluency. Scratch 
wounds were made using an automated wound maker (Essen BioScience, 
Hertfordshire, UK) and images collected at hourly intervals post-wounding using an 
IncuCyte ZOOM imaging system (Essen BioScience, Hertfordshire, UK). 
 
2.10. Statistics 
Statistical analysis performed in PRISM (GraphPad Software) using either two-way 
ANOVA with Sidak’s multiple comparison test or Student’s t-test. 
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CHAPTER 3 
 
Quantitative Phosphoproteomics Reveals a Key Role for LAR 
in Regulation of PDGF-Dependent mTOR and JNK Signalling 
Pathways 
 
3.1. Introduction 
Post-translational modifications (PTM) are involved in the regulation of almost all 
aspect of cell function (Jun Wang and Schwartz, 2016). Therefore,	characterizing and 
understanding how PTM regulated is substantial in biology of the cell in health and 
disease. One of the PTM is the phosphorylation, which control most of the biological 
processes and dysregulation is implicated in many diseases (Bode and Dong, 2004). 
Kinases and phosphatases have opposing roles in regulating the activity of proteins, 
and play a vital role in maintain cellular homeostasis through their regulation of signal 
transduction pathways (Fontanillo and Köhn, 2016, Tony Hunter, 1995). Whilst the 
role of kinases has been extensively studied, however, less is known about the 
contribution of phosphatases in regulating cell signalling pathways.  
Quantitative phosphoproteomics is a powerful technique used to identify large 
numbers of phosphorylation sites coupled to biologically informative results regarding 
regulation of these specific events. In this study, global phosphoproteomics and 
proteomics were carried out to identify and understand the cellular function which 
regulated by LAR. An additional aim was to characterise those LAR-regulated 
phosphorylation events that were PDGF dependent. We applied stable isotope 
labelling by amino acids in cell culture (SILAC) (Cunningham et al., 2010, S. E. Ong 
56	
	
et al., 2002) to characterized the phosphorylation events between mouse embryo 
fibroblasts (MEFs) obtained from mice in which the LAR cytoplasmic phosphatase 
domains had been deleted (LARΔP) and littermate wild-type (WT) mice (Schaapveld 
et al., 1997) in the absence and presence of PDGF. This type of comprehensive 
analysis of the LAR regulated phosphoproteome has not been done before. In this 
study, we identified 270 LAR-dependent phosphorylation events on 205 proteins 
which are significantly changed, including known LAR interactors, adaptor proteins, 
kinases, phosphatases, guanine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs).  
Gene ontology analysis revealed an enrichment of LAR-mediated phosphorylation 
events on proteins involved in many signalling transduction pathways including actin 
cytoskeleton, adhesion, endocytosis and cell metabolism. Kinase prediction tools and 
western blot analysis have revealed a key role for LAR in regulating mTOR and JNK 
signalling pathways. Collectively, these results significantly expand the range of 
proteins implicated downstream of LAR and provide an extensive dataset for further 
scrutiny. 
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3. 2. Results 
 
3.2.1. Evaluation of the SILAC-based phosphoproteomics 
 
First, the efficiency of SILAC labelling was analysed in WT and LARDP MEFs. WT 
and LARΔP cells were grown separately in both SILAC ‘heavy’ R10 K8 and SILAC 
‘medium’ R6K4 media for 7 doubling times. Cell lysates from each of the four cell 
populations were prepared as described in Materials and Methods chapter. Amino acid 
incorporation of both SILAC labelling media were very efficient with the average 
labelling efficiency of 96% for WT and 98% for LARDP cells (Figure 3.1). 
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Figure 3.1. SILAC label incorporation into WT and LARΔP MEFs. Each of the four raw 
files were analysed separately using MaxQuant but without selecting match between runs and 
re-quantify. Using the peptide.txt output, reverse and contaminants were removed and the % 
incorporation was calculated using the following equation: % Incorporation = (Ratio H/L or 
M/L x 100)/ (Ratio H/L or M/L + 1). 
 
 
 
After the identification of SILAC labelling technique, next we have designed the 
experimental conditions for our global proteomics and phosphoproteomics analysis. 
Three populations of WT and LARDP cells were SILAC-labelled by culturing them in 
light R0K0, medium R6K4, or heavy R10K8 SILAC media. Cells were left 
unstimulated or stimulated with PDGF-BB for 7 min (Figure 3.2).  
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Figure 3.2. Schematic overview of experimental design. Plus (+) stimulated with PDGF for 
7 min, minus (-) nonstimulated. In experiment 2 the labels were reversed. 
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A total of 30 mg of digested peptides from each experiment were divided into three 
parts and fractionated using Strong cation exchange (SCX). The elution of each part 
was combined correspondingly, resulting 20 fractions for each experiment. The SCX 
profile for representative experiment (Expt. 2) was plotted in Figure 3.3A.  Biological 
replicates 3, 4 and 5 were relatively similar with around 700 mAU, except experiment 
1 which showed the lowest UV absorbance whereas experiment 2 was the highest 
(Figure 3.3A). After desalting, the resulting 20 fractions from the SCX were 
phosphoenriched using Titanium dioxide (TiO2) tips. One of the experiment is shown 
in Figure 3.3B, we found that phosphopeptides enrichment was very efficient. 
Fraction 1 to 18 showed the best overall enrichment with average efficiency of 88%. 
In fact, it is noteworthy that fraction 19 and 20 were showed the lowest 
phosphoenrichment efficiency with more unmodified peptides (Figure 3.3B).  
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Figure 3.3. SCX profile and the efficiency of phosphopeptides. A, SCX fractionation of the 
phosphopeptides in experiment 2. B, represents the number of peptides, phosphopeptides and 
unmodified peptides being identified in each fraction of the experiment 2. The percentage of 
TiO2 enrichment efficiency was calculated by dividing the number of phosphorylation sites by 
all peptides in each fraction. 
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A total of 29,734 phosphopeptides were identified across the four biological replicates 
including redundant and non-redundant peptides, giving a total of 2,958 non-redundant 
peptides.	The overlap between all experiments is plotted as a Four-way Venn diagram 
as shown in Figure 3.4A. 54% of the phosphopeptides were identified in two or more 
replicates, whereas 27% were identified in three or more replicates. Correlation 
coefficients for the peptide ratios measured across the biological and technical 
replicates including the label swap experiment, ranged from 0.58 to 0.93 (Figure 
3.4B), indicating good biological reproducibility. 
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Figure 3.4. Overlap and correlation of phosphopeptide identifications between four 
biological repeats. A, the overlap between the four replicate experiments is plotted as a Four-
way Venn diagram. B, Pearson correlation matrix and multi scatter plots demonstrating 
reproducibility between the phosphoproteome of four biological and technical replicates. 
 
 
3.2.2. Global phosphoproteome in LARDP cells 
LAR is known to contribute to PDGF activation in fibroblasts through attenuation of 
the c-Abl activity (Zheng et al., 2011). However, the signalling consequences of this 
regulation have not been fully studied. To gain insight into the signal transduction 
pathways downstream of LAR, we utilised SILAC-based mass spectrometry (S. E. 
Ong et al., 2002) to quantitatively compare both levels of protein expression (Chapter 
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6) and phosphorylation in WT and LARDP MEFs in response to PDGF stimulation 
(Figure 3.2). Within the phosphoproteome data set, 2559 unique phosphosites from 
1311 proteins were identified with high localization scores (localization probability 
>0.75; score difference >5) in one or more biological replicates (Figure 3.5).  
Of these, the majority of phosphopeptides were singly phosphorylated with percentage 
of 79% and the remainder of phosphopeptides were either doubly (16%), triply (3%), 
or above (2%) phosphorylated peptides (Figure 3.6A). The phosphorylation sites were 
comprised of serine (83%), threonine (10%), and 7% were tyrosine phosphorylated 
sites (Figure 6B). Of these, 266 phosphosites (10%) are not listed in PhosphoSitePlus 
database (Hornbeck et al., 2012)  and are considered novel. 
 
 
 
 
 
65	
	
 
Figure 3.5. Global phosphoproteomics to measure contribution of LAR to PDGF 
signalling. Volcano plots showing the ratio (log2 fold change) and significance (–log10 
Benjamini-Hochberg adjusted p-value) of the phosphoproteome upon PDGF stimulation. 
Significantly upregulated phosphopeptides are marked in light brown box and the 
downregulated phosphopeptides are marked in pink box (adjusted p value <0.05; >1.5 fold-
change). 
 
 
In LARDP cells, a total of 270 phosphopeptides from 205 proteins showed a significant 
change in abundance (p<0.05; >1.5-fold change). Of these, 255 (95%) are serine 
phosphorylation sites, 9 (3%) threonine, and 6 (2%) were tyrosine phosphorylation 
sites indicating that LAR could contribute to the regulation of these phosphorylation 
sites via modulation of the activity of specific kinases, or via direct dephosphorylation 
for the tyrosine site. A total of 103 phosphosites were upregulated and 167 
downregulated.  
66	
	
 
 
 
Figure 3. 6. Type and classification of phosphorylated peptides within phosphoproteome 
data set.  A, Percentage of phosphorylation sites within phosphoproteome containing either 
one, two, three or more than three phosphorylation sites. B, Numbers of serine, threonine and 
tyrosine phosphorylation sites identified within our phosphoproteome data set are presented. 
	
	
	
 
3.2.3. Regulation of tyrosine phosphorylation by LAR 
Loss of LAR phosphatase activity would lead to an increase in phosphorylation of 
tyrosine residues and can be consider as a LAR potential direct substrates. Whereas, 
the downregulation tyrosine sites could be indirectly regulated by LAR. Within 
phosphoproteomics data set we found only one tyrosine phosphorylated peptide 
belonging to the Lymphocyte cytosolic protein 2 (also known as SH2 domain 
containing leukocyte protein of 76kDa; SLP76) and showed increased in abundance 
in the absence of LAR activity. SLP76 is a scaffold protein, mainly studied in T cells 
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and has been shown to enhancing T cell development in response to T cell receptors 
(J. N. Wu and Koretzky, 2004, Zeng et al., 2003). We have identified an increase in 
Tyr465 phosphorylation which is a tyrosine residue located in the SH2 domain of 
SLP76 and this protein could be direct substrate for LAR (Figure 3.7).  
 
 
 
Figure 3.7. Tyrosine phosphorylation regulated by LAR. Shows proteins and their 
phosphorylated tyrosine sites that regulated by LAR. The quantitative ratios for each site has 
been identified in three or more biological replicates. 
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However, we identified tyrosine sites that were significantly decreased in LARDP cells 
including Tensin-2 (TNS2), Rho GTPase activating protein 35 (Arhgap35; known as 
GRF1), Phosphorylase b kinase regulatory subunit alpha (PHKA1) and Signal 
transducer and activator of transcription 5A (STAT5A) (Figure 3.7). All these sites 
were downregulated supporting the notion that these proteins indirectly regulated by 
LAR. For example, we identified decreased in phosphorylation of Tyr185 on ERK2 
(Figure 3.7). The phosphorylation of this site by MEK2 induced the kinase activity 
which in turn initiating MAPK signalling pathway leading to the promotion of many 
cellular functions such as cell proliferation (Roskoski, 2012).  
To validate the phosphoproteomic data, western blotting analyses was performed 
using phospho-specific antibody targeting phosphorylation of ERK1/2. Western 
blotting analyses revealed that ERK1/2 phosphorylation is significantly reduced in 
LARDP cells when compared with WT cells upon PDGF stimulation (Figure 3.8A 
and B). Re-expression of WT LAR in LARDP cells restored the phosphorylation of 
ERK1/2, confirming that LAR phosphatase activity is required for ERK1/2 activation 
and can be a positive regulator for MAPK/ERK signalling pathway (Figure 3.8C and 
D). 
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Figure 3.8. LAR Regulates the ERK signalling pathway. A, WT and LARDP cells were 
stimulated with 20 ng/mL PDGF for the indicated time. Levels of pERK1/2 (Thr202/Tyr204), 
total ERK1/2 and Alix in whole cell lysates were analyzed by Western blotting. B, Western 
blots (n=3) were quantified and ratios of pERK to Alix were plotted over time using two-way 
ANOVA with Sidak’s test (*** p<0.001; * p<0.05). More samples have been loaded into the 
gel in time point 0 causing decrease the ratio of pERK/Alix in quantification. C, WT, LARDP, 
and LARDP cells transfected with Flag-WT-LAR, were stimulated with 20 ng/mL PDGF for 
the indicated time. Levels of pERK 1/2, total ERK and Alix in whole cell lysates were analyzed 
by Western blotting. D, Western blots (n=3) from the rescue experiments were quantified and 
ratios of pERK to Alix were plotted and statistical significance was calculated using two-way 
ANOVA with Sidak’s test (** p<0.01).  
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3.2.4. Enriched GO terms regulated by LAR 
To investigate the biological processes that may be regulated by LAR activity, Gene 
Ontology (GO) enrichment analysis was performed. Analysis of the phosphoproteome 
regulated by LAR indicated a number of enriched biological processes, molecular 
functions, and cellular components (Figure 3.9). The cytoskeletal organization and 
cell adhesion were over-presented GO terms. LAR has been previously linked to cell 
adhesions via its interaction with β-catenin (Ctnnb1) (Aicher et al., 1997). Within our 
phosphoproteomic dataset we have identified changes in abundance of specific 
phosphorylation events on a-catenin (Ser641), β-catenin (Ser191; Ser675), and d-catenin 
(Ser864), and also several proteins involved in the cell adhesion protein interaction 
network, due to the absence of LAR phosphatase activity (Figure 3.10). 
 β-catenin is a substrate for LAR, resulting in a negative regulation of tyrosine 
phosphorylation and inhibition of epithelial cell migration (T. Muller et al., 1999). 
Within our data set, we have not detected any tyrosine phosphorylation sites, instead, 
serine and threonine residues were identified such as Ser191, which is significantly 
reduced in LARΔP cells. This site has been shown to be essential for nuclear 
accumulation of β-catenin in response to Wnt and is regulated by JNK2 (X. Wu et al., 
2008). Therefore, it is possible that LAR is capable of regulating β-catenin 
phosphorylation on two levels in response to cellular signals; either by directly 
dephosphorylating specific tyrosine residues or regulation of upstream kinase activity 
such as JNK2.  
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Figure 3.9. LAR regulated distinct cellular functions. Proteins containing the 270 LAR 
regulated phosphosites were analyzed using DAVID to identify enriched GO Terms. The top 
(10) enriched categories for Biological Processes (A), Cellular Component (B) and Molecular 
Function (C) are plotted as bar charts. 
 
 
LAR has also been linked to regulation of the cytoskeleton via its interaction with 
TRIO (Debant et al., 1996). TRIO has one serine/threonine kinase domain and two 
guanine nucleotide exchange factor (GEF) domains which are involved in regulation 
of the small GTPases (Debant et al., 1996). Two TRIO phosphosites, Ser2458 and 
Ser2462 have increased in abundance in LARΔP cells indicating that in addition to 
interaction with TRIO, LAR can also regulate its phosphorylation status. Network and 
functional analysis revealed that phosphorylation for the large number of cytoskeletal 
proteins are modulated by LAR (Figure 3.10).		
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In addition, we have identified a decrease in the phosphorylation of cadherin-11 
(Ser714), plakoglobin (Ser665), ZO-1 (Ser1614), ZO-2 (Ser107; Ser239; Ser1136), providing 
an evidence that LAR regulates cell-cell adhesion and tight junctions.  
 
 
 
Figure 3.10. A network of proteins regulated by LAR. Proteins were clustered according 
to their functional keywords. Blue indicates that the protein contained a phosphosite(s) that 
was down-regulated in LARDP cells and red indicates up-regulation. 
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3.2.5. PDGF-dependent signalling events regulated by LAR 
The comparison of the phosphoproteome of WT and LARΔP cells stimulated with 
PDGF provides information regarding the proteins whose phosphorylation is regulated 
by LAR in response to PDGF stimulation. In order to specifically analyse the influence 
of PDGF on these events, phosphopeptides were clustered according to their response 
to PDGF stimulation versus unstimulated cells using GProX software (Rigbolt et al., 
2011b). We carried out two comparisons, first, PDGF-stimulated WT and LARDP 
cells versus unstimulated WT cells for the evaluation of the comparative end point of 
phosphopeptide abundance. The second comparison is between PDGF-stimulated 
LARDP cells versus unstimulated LARDP cells. In fact, our experimental design 
included three biological replicates for the ratios between PDGF-stimulated and 
unstimulated WT cells and two biological replicates for the ratios between PDGF-
stimulated LARDP cells and unstimulated WT or LARDP cells.  
We have generated six clusters as shown in Figure 3.11A. Clusters 2, 3, 4, and 6 
contained those phosphopeptides that showed a LAR-dependent events when 
compared with basal levels in WT cells. However, similar levels were observed in 
clusters 1 and 5 in both PDGF-stimulated WT and LARDP cells when compared with 
unstimulated WT cells. In clusters 2 and 3, the phosphopeptides showed no differences 
in abundance upon PDGF stimulation in WT and LARDP cells compared with their 
basal levels. In contrast, PDGF stimulated LARDP cells was significantly changed 
compared with unstimulated WT cells. Moreover, a similar fold change was observed 
in clusters 4 and 6 in LARDP cells upon PDGF stimulation when compared with either 
unstimulated WT or LARDP cells. 
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GO terms enrichment analysis for these clusters showed a discrete between the cellular 
component and molecular functions regulated by these groups of phosphoproteins 
(Figure 3.11B and C). The majority of over-presented GO terms in cellular 
components are cytoskeletal, focal adhesion, endosomes and vesicular compartments. 
Cluster 4 is shows the most interesting because it contains phosphorylation sites that 
are significantly increased in response to PDGF (Figure 3.11C). Cytoskeletal proteins 
were enriched in cluster 4 including proteins play a role in regulation of actin 
reorganisation and stress fiber formation such as Vinexin (Sorbs3) (Kioka et al., 1999). 
This cluster also contains g-adducin (Add3), a protein involved in regulation of tight 
junctions (Naydenov and Ivanov, 2011). We detected 3-fold reduction in 
phosphorylation of Ser669 on Sorbs3 and Ser423 on Add3 in LARDP cells upon PDGF 
stimulation. In addition, we observed enriched cellular component in cluster 6 
including lysosomal membrane, endosome and microtubule (Figure 3.11B). This is 
supporting the notion that LAR involved in regulation of distinct biological processes 
and highlight the cooperation between PDGF and LAR in modulation of the 
cytoskeleton and protein transport.  
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Figure 3.11. Phosphorylation events in WT and LARDP cells show clusters of regulation 
correlated to distinct biological processes. A, GProX clustering of phosphopeptide 
abundance changes. Ratios of PDGF-stimulated WT and LARDP cells over WT unstimulated 
cells and PDGF-stimulated LARDP cells over LARDP unstimulated cells were subjected to 
unsupervised clustering using the fuzzy c means algorithm. The number of phosphopeptides 
in each cluster is indicated. Overrepresentation of cellular components (B) and molecular 
function (C) in the clusters are represented as a heat map. GO terms were performed within 
GProX using a binomial statistical test with a Benjamini-Hochberg p-value adjustment (p-
value threshold 0.05). 
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3.2.6. Kinase predication analysis revealed LAR regulates distinct 
kinase nodes 
Kinases are key regulators of phosphorylation events in signalling pathways, and those 
kinases whose activity is regulated by LAR phosphatase activity would have altered 
regulation in LARΔP cells. In order to identify key nodes of regulation within our 
phosphoproteome dataset, the kinase prediction tool GPS (Xue et al., 2008) was used 
to identify predicted upstream kinases of those phosphorylation peptides that showed 
significant changes (270 phosphopeptides). GPS predicts upstream kinases based on 
substrate sequence specificity, protein-protein interactions and experimentally 
determined protein-protein interactions, combined with the high stringency setting.  
Prior to analysis, by taking an advantage of our proteome data set, any of the proteins 
showed similar fold change in abundance in expression to the change in 
phosphorylation were removed in order to assured that the change in phosphorylation 
was not a result of change in protein expression. We found 223 phosphopeptides as 
putative substrates for a particular kinase. Members of the CMGC family (includes 
Cyclin-dependent kinases, Mitogen-activated protein kinases, Glycogen synthase 
kinases and CDK-like kinases) were predicted to phosphorylate the majority of 
phosphosites (Figure 3.12). The most predominant predicted kinase was the 
CMGC/CDK family and CMGC/MAPK subfamily, including ERK, JNK, and p38 
kinases. Another predominant kinase was mTOR (Figure 3.12). Therefore, we 
decided to investigate if LAR regulates mTOR and JNK signalling pathways. 
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Figure 3.12. LAR Regulates Distinct Kinase Nodes. Phosphorylation sites regulated by 
LAR were searched using the kinase prediction tool GPS. All kinases predicted to 
phosphorylate at least five identified phosphorylation sites are displayed. Each node represents 
an individual kinase or group/family of kinases and colored according to kinase family (see 
key for details). An edge (line) connecting two nodes indicates that the corresponding kinase 
groups were predicted to phosphorylate at least one common residue (clustered nodes were 
predicted to phosphorylate similar residues). Node size corresponds to the total number of 
LAR regulated phosphorylation sites that were predicted to be phosphorylated by the 
corresponding kinase. 
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3.2.7. JNK signalling pathway is regulated by LAR 
By using GPS tool, JNK1 was predicted for regulation of 53 motifs in our 
phosphoproteome data set (Figure 3.12). The predicted JNK substrates (53 motifs) 
were then submitted to Motif-x (Schwartz and Gygi, 2005) to evaluate these potential 
substrates. We found proline-directed phosphorylation motif [(P)-X-S/T-P] was 
enriched (Figure 3.13). This consensus motif has been found in most JNK substrates 
and can also be phosphorylated by MAPKs and CDKs (Bogoyevitch and Kobe, 2006, 
Davis, 2000).  
 
 
 
Figure 3.13. Identification of JNK consensus motif. Phosphorylation motifs that were 
enriched above the mouse proteome using Motif-x. 
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Number of interesting proteins belonging to these motifs were predicted to be 
regulated by JNK such as Stathmin1 (Stmn2), microtubule protein involved in 
regulation of destabilizing microtubule filament (Wittmann et al., 2004). JNK is 
known to phosphorylate Stmn2 at Ser62 and inhibit its affinity towards tubulin (Tararuk 
et al., 2006). Within our phosphoproteome data set, we found this site significantly 
reduced in LARDP cells compared with WT. Taken together, these finding prompted 
us to investigate whether LAR regulates JNK signalling pathway.  
Immunoblotting analysis showed a significant reduction in the activity of JNK in 
LARDP cells when compared with WT in response to PDGF stimulation (Figure 
3.14). MKK4 and MKK7 act as upstream of JNK and can activate JNK by the 
phosphorylation of Tyr185 and Thr183 residues, respectively (Davis, 2000, Lawler et al., 
1998). The activity of MKK7 was also reduced in LARDP cells (Figure 3.14). Active 
JNK leads to control the activity of many transcription factors including c-Jun, JunB, 
JunD, ATF2, Stat1 and Stat3 (Bogoyevitch and Kobe, 2006). For instance, JNK can 
activates c-Jun by the phosphorylation of Ser63 residue (Derijard et al., 1994).  
Therefore, we decided to investigate the activity of c-Jun in WT and LARDP cells. In 
line with MKK7 and JNK data, a significant decreased was observed in the 
phosphorylation of c-Jun at Ser63 in LARDP cells (Figure 3.14). 
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Figure 3.14. LAR Regulates the JNK signalling pathway. A, WT and LARDP cells were 
stimulated with 20 ng/mL PDGF for differing periods of time as indicated. Levels of JNK 
Thr183/Tyr185, total JNK, MKK7 Ser271/Thr275, total MKK7, c-Jun Ser63, c-Jun and Alix 
in whole cell lysates were analyzed by Western blotting. B–D, Western blots (n=3) were 
quantified and ratios of phospho-protein to total protein were plotted over time and statistical 
significance was calculated using two-way ANOVA with Sidak’s test (*** p<0.001; ** 
p<0.01; * p<0.05).  
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Re-expression of WT LAR in LARDP cells restored JNK activity (Figure 3.15). These 
data indicating that LAR is required for JNK activity and plays a role in regulating 
PDGF-mediated JNK signalling pathway.  
 
 
 
Figure 3.15. LAR is required for JNK activity. A, WT, LARDP, and LARDP cells 
transfected with Flag-WT-LAR were stimulated with 20 ng/mL PDGF for 7 min (this time 
point was used because the SILAC experiment was done at this time point and higher 
PDGFR phosphorylation was also recorded at 7 min). Levels of JNK Thr183/Tyr185, 
total JNK, Flag-LAR and Alix in whole cell lysates were analyzed by Western blotting. B, 
Western blots (n=3) from the rescue experiments were quantified and ratios of JNK 
Thr183/Tyr185 to total JNK were plotted and statistical significance was calculated using two-
way ANOVA with Sidak’s test (** p<0.01). 
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3.2.8. LAR regulates mTOR signalling 
mTOR is an atypical serine/threonine protein kinase and can binds to several proteins 
to form two complexes, mTORC1 and mTORC2 to regulate a diverse cellular 
functions including protein synthesis, energy metabolism and cytoskeletal 
organisation (Laplante and Sabatini, 2012). The mTOR signalling pathway is tightly 
controlled by upstream regulators. It has been reported that Ras homolog enriched in 
brain (Rheb) GTPase can interacts with mTORC1 to promotes its kinase activity (Inoki 
et al., 2003). While tuberous sclerosis 1 (TSC1) and TSC2 act as a negative regulator 
for mTOR activity by converting the GTP-Rheb active form to GDP-Rheb inactive 
form (Tee et al., 2003).  
In addition, mTOR is also regulated by Akt through directly phosphorylate TSC2 at 
Ser939 and Thr1462 thus promoting mTOR activation which in turn enhance Ribosomal 
protein S6 kinase (p70S6K) and Eukaryotic translation initiation factor 4E (eIF4E) 
activity (Inoki et al., 2005, Q. Yang and Guan, 2007).  
Kinase prediction analysis revealed mTOR as a prominent node of regulation by LAR 
(Figure 3.12). In order to validate the bioinformatics data and to investigate whether 
LAR is regulating mTOR activity, we used antibodies targeting phosphorylated Ser2448 
on mTOR and phosphorylated Thr389 on p70S6K, an mTOR downstream effector. The 
phosphorylation of mTOR on Ser2448 significantly increased upon stimulation with 
PDGF (Figure 3.16A and B). However, the absence of LAR phosphatase activity 
resulted in a significant reduction in the phosphorylation of this site (Figure 3.16A 
and B). In addition, western blotting analysis of the phosphorylation of p70S6K at 
Thr389 showed a similar response to that seen with mTOR phosphorylation establishing 
a noel role for LAR in regulation of mTOR activity (Figure 3.16A and C).  
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Figure 3.16. LAR regulates the mTOR signalling pathway. A, WT and LARDP cells were 
stimulated with 20 ng/mL PDGF for indicated time periods. Levels of mTOR Ser2448, total 
mTOR, P70S6 Thr389, and Alix in whole cell lysates were analyzed by Western blotting. B, 
C, Western blots (n=3) were quantified and ratios of phospho-proteins to Alix were plotted 
over time and statistical significance was calculated using two-way ANOVA with Sidak’s test 
(*** p<0.001; ** p<0.01; *p<0.05). 
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The phosphorylation of mTOR at Ser2448 was restored by re-expression of WT LAR 
in LARDP cells (Figure 3.17) confirming a novel role for LAR in the regulation of 
mTOR signalling. It’s noteworthy that the expression of WT LAR can also enhance 
the phosphorylation of mTOR at time point 0 indicating that LAR could regulate 
mTOR phosphorylation in PDGF-independent manner. 
 
 
 
 
Figure 3.17. LAR is required for mTOR activity. A, WT, LARDP, and LARDP cells 
transfected with Flag-WT-LAR were stimulated with 20 ng/mL PDGF for 7 min. Levels of 
mTOR Ser2448, total mTOR, FLAG-LAR and Alix in whole cell lysates were analyzed by 
Western blotting. B, Western blots (n=3) from the rescue experiments were quantified and 
ratios of mTOR Ser2448 to Alix were plotted and statistical significance was calculated using 
two-way ANOVA with Sidak’s test (*** p<0.001; ** p<0.01; * p<0.05). 
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It has been shown that JNK promotes mTORC1 activity by phosphorylation of Raptor, 
one of the mTORC1 component, at Ser863 (Fujishita et al., 2011). However, the 
underling mechanism on how JNK crosstalk with mTOR signalling remain unstudied. 
Therefore, we examined whether JNK control the activity of mTOR by applying JNK 
inhibitor (SP600125). SP600125 has been widely used to study JNK signalling 
(Bennett et al., 2001, Q. H. Guan et al., 2005, W. Wang et al., 2004). WT MEFs were 
treated with SP600125 or DMSO and the phosphorylation of mTOR at Ser2448 in 
response to PDGF stimulation was examined. The phosphorylated Ser2448 was reduced 
upon SP600125 treatment (Figure 3.18). SP600125 could inhibit JNK signalling as 
the phosphorylation of JNK and the downstream effector c-Jun were also decreased 
(Figure 3.18). These finding demonstrate that JNK may involve in regulation of 
mTOR activity. 
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Figure 3.18. JNK regulates mTOR activity. A, WT MEFs were treated with an JNK 
inhibitor (SP600125) or DMSO (control) for 2 hrs before being stimulated with 20 ng/mL 
PDGF-BB for 14 minutes. Levels of pmTOR Ser2448, total mTOR, pJNK Thr183/Tyr185, 
total JNK, pc-Jun Ser63, total c-Jun and Alix in whole cell lysates were analyzed by 
immunoblotting. B, Western blots (n=3) were quantified and ratios of pmTOR to Alix were 
plotted and statistical significance was calculated using two-way ANOVA with Sidak’s test 
(*** p<0.001). 
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3.3. Discussion 
 
Post-translational modifications are involved in the regulation of multiple cellular 
functions (Jun Wang and Schwartz, 2016). Therefore,	 characterizing and 
understanding on how PTM regulated is substantial in biology of the cell in health and 
disease (Deribe et al., 2010). Signal transduction pathways that regulated by LAR have 
not been studied, therefore global quantitative phosphoproteomics and proteomics 
were carried out in order to provide an extensive study of signalling events regulated 
by LAR.  
Within the phosphoproteome data set, 2559 unique phosphosites from 1311 proteins 
were identified with high localization scores (localization probability >0.75; score 
difference >5) in one or more biological replicates. A total of 270 phosphopeptides 
from 205 proteins showed a significant change in abundance (p<0.05; >1.5-fold 
change) in LARDP cells upon PDGF stimulation. Of these, 255 (95%) are serine 
phosphorylation sites, 9 (3%) threonine, and 6 (2%) were tyrosine phosphorylation 
sites. In addition, a total of 103 phosphosites were significantly upregulated and 167 
downregulated. It is possible that LAR contributes to the regulation of these 
phosphorylation sites via modulation of the activity of specific kinases, or via direct 
dephosphorylation of the tyrosine sites. 
Most of the previous studies were focused on the role of LAR in the regulation of 
nervous system including neuronal development, growth, neuronal regeneration and 
axon guidance (Mélanie J Chagnon et al., 2004a, Sethi et al., 2010, Fang Wang et al., 
2012, Julie S Zhang and Longo, 1995). However, GO terms analysis revealed an 
enrichment of LAR-mediated phosphorylation events on proteins which are involved 
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in many signal transduction pathways including actin cytoskeleton, adhesion, 
endocytosis and metabolism. Within phosphoproteome data set, TRIO, and b-catenin 
were identified. These proteins have been shown as a direct substrate for LAR (Debant 
et al., 1996, Dunah et al., 2005, Kypta et al., 1996, T. Muller et al., 1999). TRIO is an 
adaptor protein which acts as a GEF for Rac and Rho small GTPases (Debant et al., 
1996). b-catenin a protein involved in regulation of cell-cell adhesions (Harris and 
Tepass, 2010). β-catenin is a substrate for LAR, resulting in a negative regulation of 
tyrosine phosphorylation and inhibition of epithelial cell migration (T. Muller et al., 
1999). Within our data set, the phosphorylation of β-catenin at Ser191 was significantly 
reduced in LARΔP cells. This site has been shown to be essential for nuclear 
accumulation of β-catenin in response to Wnt and is regulated by JNK2 (X. Wu et al., 
2008). 
Kinase prediction and motifs analysis have identified a key role for LAR in regulating 
ERK, mTOR and JNK signalling pathways in response to PDGF stimulation. These 
data have been confirmed by immunoblotting. Interestingly, the re-expression of WT 
LAR in LARDP MEFs rescued the activity of these signalling pathways providing 
further support that PDGF-induced mTOR, ERK and JNK pathways is LAR-
dependent phenotype. Collectively, these results significantly expand the range of 
proteins implicated downstream of LAR and provide a comprehensive dataset for 
further investigation.  
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CHAPTER 4 
LAR Protein Tyrosine Phosphatase Regulates Focal Adhesions 
via CDK1 
 
4.1. Introduction 
Cell adhesion to the extracellular matrix (ECM) components is essential for several 
fundamental cellular processes including cell signalling, differentiation, proliferation, 
motility and survival. Focal adhesions (FA) are composed of a number of protein 
molecules and mediate transfer of signals from ECM to the cytoplasm as well as 
nucleus and further regulate biological functions. For instance, integrins can bind to 
the extracellular molecules leading to autophosphorylation of focal adhesion kinase 
(FAK) resulting in activation of cascade of downstream signalling proteins (Guo and 
Giancotti, 2004). In addition, the role of receptor tyrosine kinase (RTK) such as 
platelet-derived growth factor receptor (PDGFR) in cell adhesion mediated via FAK 
has also been established (Sieg et al., 2000).  
Many studies have found that Drosophila LAR (DLAR) play a role in remodelling 
synaptic actin (Johnson et al., 2006, Sethi et al., 2010). It has also been demonstrated 
that the LAR-interacting protein 1 (LIP.1) binds to LAR phosphatase domain (D2) and 
recruits it to focal adhesions (Serra-Pages et al., 1995), indicating that LAR could play 
a crucial role in cell adhesion. However, no evidence for the role of LAR in regulating 
cell adhesion is currently available. Therefore, we have investigated the role of LAR 
in cell adhesion. 
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The non-receptor tyrosine kinase Abelson murine leukaemia viral oncogene (c-Abl) is 
non-receptor tyrosine kinase which involved in regulating many signalling pathways 
such as proliferation, migration, morphogenesis and apoptosis (Hernandez et al., 2004, 
Keshet et al., 2015, Levy et al., 2008). It has shown to localized in cytoplasm, cell 
membrane, nucleus as well as actin cytoskeleton region (Van Etten, 1999). c-Abl is 
highly controlled and regulated by intramolecular interactions to prevent oncogenic 
activity of the protein. In 2004 Hantschel and Superti-Furga demonstrated that these 
interactions keep the kinases domain closed and inactive (Hantschel and Superti-
Furga, 2004). The phosphorylation of Tyr245 and Tyr412 can cause conformation in 
order to activate c-Abl (Hantschel and Superti-Furga, 2004, Harrison, 2003). 
Nevertheless, any disruption in these interactions leads to transforming and oncogenic 
activity in c-Abl. C-Abl can interact and activate by PDGFβR in response to PDGF 
stimulation and it has been shown to play a crucial role in PDGFβR downstream 
signalling pathways (Plattner et al., 1999). Researchers indicated that c-Abl is 
phosphorylated and activated directly by binding to the PDGFβR via SH2 domain or 
indirectly by Src family kinases, which in turn phosphorylate Tyr245 and Tyr412 in 
activation loop of c-Abl protein (Plattner et al., 1999). 
Cyclin-dependent kinase 1 (CDK1) is a serine/threonine kinase encoded by cdc2 gene 
and a key regulator in cell cycle progression (Enserink and Kolodner, 2010). CDK1 
activity is highly maintained and regulated by multistep process involving the 
association with cyclin B1, phosphorylation of Thr161 by a CDK activating kinase 
(CAK) and finally dephosphorylation of Thr14 and Tyr15 by CDC25 (Rhind and 
Russell, 2012).  
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Our results demonstrate that the deletion of LAR phosphatase domains leads to a 
significant reduction of focal adhesion complexes and cell adhesion to fibronectin 
compared with WT cells.  To establish how LAR regulates cell adhesion, we used our 
phosphoproteome data set to identified a target regulated by LAR. As indicated in 
Figure 3.12 (Chapter 3), CDK1 was predicated to phosphorylate the majority of 
phosphosites. Closer inspection of the phosphoproteome data revealed that loss of 
LAR phosphatase activity was associated with altered phosphorylation of CDK1 at 
Thr161. Immunoblotting and microscopy analysis established that c-Abl acts 
downstream of LAR to regulate CDK1 activity via Akt.  
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4.2. Results 
4.2.1. Cell adhesion and focal adhesion formation require LAR 
phosphatase activity	
To analyse whether LAR might play a role in cell adhesion, the formation of adhesion 
complexes and cell adhesion to ECM were investigated. WT or LARDP cells were 
serum-starved overnight before being stimulated with 20 ng/mL PDGF-BB for 14 
minutes and stained using an anti-phospho-paxillin (Tyr118) antibody to visualise 
adhesion complexes. Treatment of WT cells with PDGF resulted in increased in focal 
adhesions compared to untreated cells (Figure 4.1A and B). Since LARDP cells can 
spread and could make focal adhesions under normal condition, however, treatment of 
LARDP cells with PDGF resulted in significantly fewer focal adhesions compared 
with WT cells (Figure 4.1A and B).  
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Figure 4.1. Loss of LAR phosphatase activity is associated with decreased adhesion 
complex formation. A, WT and LAR∆P MEFs were serum-starved overnight before being 
treated with 20 ng/mL PDGF-BB for 14 minutes. Cells were fixed and permeabilised and then 
stained using an antibody against phosphorylated paxillin Tyr118 to visualise adhesion 
complexes. Nuclei were visualised using DAPI. Scale bar represents 20 µm. B, the cell area 
occupied by adhesion complexes was quantified using ImageJ and expressed as a percentage 
of the total cell area (one-way ANOVA with post hoc Tukey’s test; ** p<0.01; *** p<0.001). 
 
Having observed decreased adhesion complex formation in LARDP cells, next we 
analysed whether LAR phosphatase activity contributes to cell attachment to ECM 
protein such as fibronectin. WT and LARDP cells were allowed to attach to fibronectin 
in the presence or absence of 20 ng/mL PDGF-BB for 30 minutes (Figure 4.2A). 
LARDP cells were significantly impaired in their ability to attach to fibronectin when 
compared to WT cells (Figure 4.2A). In the presence of PDGF a slight but not 
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significant increase in attachment to fibronectin was observed in WT cells but 
treatment with PDGF had no effect on LARDP cells (Figure 4.2A). 
To confirm the adhesion phenotype was specific for LAR, we used RNA interference 
to knockdown expression of LAR in WT cells. Transfection of WT cells with LAR 
siRNA oligos resulted in a significant decrease in cell attachment to fibronectin 
(Figure 4.2B and C). We also examined whether LAR regulates cell migration using 
wound healing assay and we found no significant changes between WT and LARDP 
cells (Figure 4.2D). These findings indicated that LAR regulates the formation of 
adhesion complexes and cell attachment to fibronectin but not cell migration in MEFs. 
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Figure 4. 2. LAR phosphatase is required for optimal cell adhesion to fibronectin. A, WT 
and LAR∆P MEFs were allowed to attach to fibronectin for 30 minutes in the presence or 
absence of 20 ng/mL PDGF-BB.  B, C, WT MEFs were transiently transfected with siRNA 
oligos targeted against LAR or with control non-silencing oligos (NSC). 48 hours after 
transfection cells were serum-starved overnight and either (B) cell lysates were prepared for 
immunoblotting with antibodies against LAR and Alix or (C) cells were allowed to attach to 
10 µg/mL fibronectin as described in A. Statistical significance (n=3) was calculated using 
Student’s T test (*** p<0.001). 
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4.2.2. Focal adhesion kinase is not affected by LAR 
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase frequently linked to 
adhesion complex formation and cell adhesion (Mitra et al., 2005, Seong et al., 2011). 
However, recent study showed that the inhibition of FAK or Src is not affected 
adhesion complex composition (Horton et al., 2016). As FAK is also known to play a 
role in integration of integrin and growth factor signalling and can also phosphorylate 
paxillin on Tyr118 (Sieg et al., 2000), we asked whether LAR was regulating adhesion 
complex formation through FAK. To do this we used phospho-specific antibodies 
raised against Tyr397 and Tyr407 of FAK. Tyr397 is an autophosphorylation site, which 
when phosphorylated recruits c-Src which then further phosphorylates other tyrosine 
residues to which src-homology 2- (SH2) domain containing proteins can bind (Calalb 
et al., 1995). Phosphorylation of Tyr407 results in optimal FAK catalytic activity 
(Boivin et al., 2013). Consistent with immunostaining of adhesion complexes (Figure 
4.1) we observe significantly reduced paxillin Tyr118 phosphorylation in both serum-
starved and PDGF-stimulated LARDP cells (Figure 4.3A). However, when we 
analysed FAK activity in LARDP cells we observed no significant difference in 
phosphorylation of either Tyr397 or Tyr407 when compared to WT cells (Figure 4.3B-
D). This would indicate that LAR does not regulate activity of FAK and would be 
consistent with previous observation that activation of c-Src is not regulated by LAR 
(Zheng et al., 2011). In summary, these data demonstrated that the regulation of 
adhesion complexes by LAR is independent of FAK activity. 
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Figure 4. 3. FAK tyrosine phosphorylation is unaffected by loss of LAR activity. A, B, 
Serum-starved WT and LAR∆P MEFs were stimulated with 20 ng/mL PDGF-BB for indicated 
time periods before protein lysates were prepared and immunoblotted using antibodies against 
(A) paxillin and phospho-paxillin Tyr118 or (B) FAK, phospho-FAK Tyr397 and phospho-
FAK Tyr407. C, D, the ratio of either phosphorylated FAK Tyr407 (C) or phosphorylated 
FAK Tyr397 (D) to total FAK was calculated using densitometric analysis of immunoblots 
(n=3). 
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4.2.3. Phosphoproteomic analysis identifies a role for CDK1 in 
regulation of focal adhesions 
To establish how LAR regulates cell adhesion, we used kinase predication tool (GPS) 
for our phosphoproteome data set to identified a target regulated by LAR. CDK1 was 
predominant and predicated to phosphorylate the majority of phosphosites as shown 
in Figure 3.12 (Chapter 3). We have identified 38 putative substrates for CDK1 and 
50% of the 38 predicated substrates have been found in adhesome (Horton et al., 2015).  
CDK1 putative substrates are also including adhesion related-proteins including: 
Tenc1, a phosphoprotein that localized to focal adhesions (Lo, 2004, Moon et al., 
2012); Tjp2, a protein involved in the regulation of adherent and tight junctions (Itoh 
et al., 1999) and Mllt4, a cell adhesion binding protein (Ikeda et al., 1999) (Figure 
4.4).  
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Figure 4. 4. Network of CDK1 putative substrates. CDK1 substrates were analysed using 
the Group-based Prediction System (GPS). Of 270 phosphopeptides, 38 were identified as 
potential CDK1 substrates. Protein-protein interaction network analyses were performed using 
Cytoscape. Nodes are clustered according to functional group and nodes identified as being 
part of the meta-adhesome are highlighted with a red border. 
 
 
In addition, phosphoproteomics analysis identified Thr161 was down-regulated in 
LARDP cells suggesting LAR is required for phosphorylation of this key regulatory 
residue in the activation loop of CDK1 (Solomon et al., 1992, Ubersax et al., 2003). 
Therefore, the role of CDK1 in cell adhesion was investigated and asked whether LAR 
regulates cell adhesion via CDK1. To confirm the phosphoproteomics data, we used a 
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phospho-specific antibody to detect Thr161 phosphorylation and hence CDK1 
activation status in WT and LAR∆P cells. The phosphorylation of CDK1 at Thr161 was 
higher in WT compared with LAR∆P cells upon PDGF stimulation (Figure 4.5A). 
CDK activity also requires association with cyclin B1 during G2/M (Malumbres, 
2014), we asked whether LAR might regulates this interaction.	In fact, there were no 
differences in expression of cyclin B1 or the interaction with CDK1 (Figure 4.5B). 
Thus, our data indicate LAR phosphatase activity is required for phosphorylation of 
CDK1 Thr161 but not affecting the association with cyclin B1. 
Having observed phosphorylation events in LAR∆P cells consistent and identified 
CDK1 potential substrates which are adhesion-related proteins, we examined whether 
CDK1 might also regulate adhesion complex formation in WT MEFs. To visualise 
adhesion complexes, we immunostained cells using an antibody to phosphorylated 
Tyr118 on paxillin.  Treatment of WT cells with RO-3306, a specific inhibitor of CDK1, 
resulted in significantly fewer focal adhesions (Figure 4.5C). To confirm that this 
phenotype is via CDK1 downstream of LAR, rescue experiment was done in LAR 
cells by transiently expressed a constitutively active form of CDK1 (T14A; Y15F; 
cannot be phosphorylated at Thr14 and Tyr15) (Hagting et al., 1998). The expression of 
CDK-AF resulted in a significant increase in focal adhesions (Figure 4.5D). These 
finding indicate CDK1 act as a downstream of LAR phosphatase to regulate the 
formation of focal adhesion in MEFs. 
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Figure 4. 5. CDK1 functions downstream of LAR to regulate focal adhesion complex 
formation. A, Serum-starved WT and LAR∆P cells were stimulated with 20 ng/mL PDGF-
BB for increasing periods of time before protein lysates were prepared and immunoblotted 
using antibodies against CDK1, CDK1 phospho-Thr161, cyclin B1 and Alix. B, WT and 
LAR∆P MEFs were stimulated with 20 ng/mL PDGF-BB for 7 min, Cyclin B1 
immunoprecipitated and immunoblotted with CDK1 or Cyclin B1. C, WT MEFs were treated 
with a CDK1 inhibitor (RO-3306) or DMSO (control) for 60 minutes before being stimulated 
with 20 ng/mL PDGF-BB for 14 minutes, fixed and stained with a phospho-paxillin (Tyr118) 
antibody to visualise focal adhesions. Scale bar represents 20 µm. D, LARΔP cells were 
transfected with constitutively active form of CDK1 (CDK1-AF) before being stimulated with 
20 ng/mL PDGF-BB for 14 minutes and stained with a phospho-paxillin (Y118) antibody. The 
cell area occupied by adhesion complexes was calculated using ImageJ and expressed as a 
percentage of the total cell area (Student’s T test; *** p<0.001). Scale bar represents 20 µm. 
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4.2.4. LAR phosphatase signals to CDK1 through Akt 
Activation of the serine/threonine kinase Akt downstream of PI3K is a well-
established PDGF-regulated pathway, and previous work has established that LAR 
regulates PDGF-mediated activation of Akt (Zheng et al., 2011). Activation of Akt 
requires phosphorylation of Thr308 in the activation loop (Alessi et al., 1996). 
Therefore, to confirm that LAR regulates Akt downstream of PDGFbR, phospho-
specific antibody raised against Thr308 was used. In control, serum-starved WT cells, 
the stimulation with PDGF resulted in a rapid increase in phosphorylation of Akt at 
Thr308 whereas in LAR∆P cells phosphorylation of Thr308 was significantly reduced 
(Figure 4.6A and B).  
Regulation of CDK1 activity is complex but Akt1 has previously been reported to be 
required for phosphorylation of CDK1 at Thr161 (Nogueira et al., 2012) suggesting Akt 
may be part of the pathway downstream of LAR and PDGFbR leading to activation of 
CDK1 and regulation of adhesion complex formation. To identify whether LAR 
regulates adhesion complex formation via Akt and CDK1, we first analysed activity 
of CDK1 in WT cells treated with a specific Akt inhibitor (InSolution Akt Inhibitor 
VIII). Treatment of PDGF-stimulated WT cells with this inhibitor resulted in a 
reduction of Thr161 phosphorylation on CDK1 suggesting Akt-dependent activation of 
CDK1 (Figure 4.6C). To analyse whether Akt was also playing a role in LAR-
dependent cell adhesion we analysed adhesion complex formation in WT cells treated 
with the Akt inhibitor (Figure 4.6D). We observed a decrease in adhesion complex 
formation compared to control, vehicle (DMSO) treated cells providing further 
evidence of a novel role for LAR in regulation of cell adhesion via CDK1. 
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Figure 4. 6. Akt is required for LAR-mediated regulation of CDK1 and adhesion complex 
formation. A, Serum-starved WT and LAR∆P MEFs were stimulated with 20 ng/mL PDGF-
BB for increasing periods of time before protein lysates were prepared and immunoblotted 
using antibodies against Akt, phospho-Akt Thr308 and Alix. B, Densitometric analysis of data 
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from 3 independent experiments using ImageJ and statistical significance was calculated using 
two-way ANOVA with Sidak’s test (*** p<0.001). C, Serum-starved WT MEFs were 
stimulated with 20 ng/mL PDGF-BB for increasing periods of time in the presence of Akt 
inhibitor (InSolution Akt Inhibitor VIII) or DMSO (control) before protein lysates were 
prepared and immunoblotted using antibodies against CDK1, phospho-CDK1 Thr161 and Alix. 
D, WT MEFs were treated with an Akt inhibitor (InSolution Akt Inhibitor VIII) or DMSO 
(control) overnight before being stimulated with 20 ng/mL PDGF-BB for 14 minutes and 
stained with a phospho-paxillin (Tyr118) antibody. The cell area occupied by adhesion 
complexes was calculated using ImageJ and expressed as a percentage of the total cell area 
(Student’s T test; *** p <0.001). Scale bar represents 20 µm. 
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4.2.5. c-Abl is a mediator connecting LAR and Akt/ CDK1  
It has been previously shown that LAR-mediated inhibition of the protein tyrosine 
kinase c-Abl and was required for maximal PDGF receptor signalling (Zheng et al., 
2011). C-Abl is also involved in regulation of integrin-mediated cell adhesion and 
actin cytoskeletal reorganisation (Lewis and Schwartz, 1998, J. Y. Wang, 2014, 
Woodring et al., 2003). Therefore, we decided to examine whether c-Abl is a substrate 
for LAR. HEK 293T cells were transiently transfected with either LAR WT or LAR 
substrate trapping mutants LAR C/S (C1548S); LAR D/A (D1516A) (Figure 4.7A) 
(W. J. Wang et al., 2007). Protein tyrosine phosphatases (PTP) substrate trapping 
mutants have been commonly used to identified physiological substrates. These 
mutations and name ‘Substrate-trap’ were firstly discovered by Tonks lab (Flint et al., 
1997, Jia et al., 1995, Sun et al., 1993).  
To this end, the when the PTP binds to phosphorylated tyrosine residue on the substrate 
for dephosphorylation, substrate can trap in the catalytic pocket of the protein tyrosine 
phosphatase (Blanchetot et al., 2005, Flint et al., 1997). By using this method, we 
identified c-Abl as direct substrate for LAR and can binds to LAR WT and LAR 
substrate trapping mutants (Figure 4.7B). Interestingly, a reduction was observed in 
total phosphotyrosine on Abl when compared to cells expressing Abl only (Figure 
4.7B). These data clearly demonstrate that c-Abl is a direct substrate for LAR in 
mammalian cells.  
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Figure 4. 7. Substrate-trapping mutants approach identified c-Abl as a substrate for 
LAR. A, Schematic structure of LAR substrate-trapping mutants. Full-length FLAG-tagged 
wild-type LAR (WT), substrate-trapping mutants C/S (Cys1548 in D1 domain replaced by 
Ser1548) and D/A (Asp1516 in D1 domain replaced by Ala1516). Ig, immunoglobulin-like 
domain; FNIII, fibronectin type III repeat domain; TM, transmembrane; D1, protein tyrosine 
phosphatase domain 1; D2, protein tyrosine phosphatase domain 2. B, FLAG-tagged wild-
type LAR (WT) and substrate-trapping mutants of LAR along with WT c-Abl were either 
expressed alone or co-expressed in HEK 293T cells. c-Abl was immunoprecipitated using a 
c-Abl antibody and immunoprecipitates were immunoblotted with either LAR, c-Abl or total 
phosphotyrosine (PY99) antibodies. To control for expression levels, whole cell lysates 
(WCL) were immunoblotted with FLAG antibody.  
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After identified LAR interacted with c-Abl, next we tested whether c-Abl involved in 
regulation of CDK1 or Akt. To do so, LARDP cells were treated with c-Abl inhibitor 
(AG957) and the activity of Akt and CDK1 were assessed. Inhibition of c-Abl resulted 
in increased in activity of Akt and CDK1 (Figure 4.8). These finding suggest that c-
Abl could be a mediator linking LAR with Akt/CDK1 and establishing a signalling 
pathway connecting LAR and cell adhesion.  
 
 
Figure 4. 8. Inhibition of c-Abl restored the activity of Akt and CDK1. A, Serum-starved 
LARDP cells were stimulated with 20 ng/mL PDGF-BB for increasing periods of time in the 
presence of a c-Abl inhibitor (AG957) or DMSO (control) before protein lysates were prepared 
and immunoblotted using antibodies against Akt, phospho-Akt Thr308 and Alix, or CDK1, 
phospho-CDK1 Thr161 and Alix (C). B, D, both CDK1 and Akt blots from 3 independent 
experiments were analysed using ImageJ and statistical significance was calculated using two-
way ANOVA with Sidak’s test (** p < 0.01; * p < 0.05). 
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4.3. Discussion 
Most of the previous studies were focused on the role of LAR in the regulation of 
nervous system including neuronal development, growth, neuronal regeneration, axon 
guidance and have been mostly done on the Drosophila ortholog, DLAR (Mélanie J 
Chagnon et al., 2004a, Sethi et al., 2010, Fang Wang et al., 2012, Julie S Zhang and 
Longo, 1995). DLAR has been shown to localize to synaptic junctions for the 
regulation of axonal guidance through Rho family GTPases (Bateman et al., 2000, 
Kaufmann et al., 2002, C. Pawson et al., 2008). Here, a significant decreased in cell 
adhesion and the formation of focal adhesion were observed in the absence of LAR 
activity demonstrating a key role for LAR in regulation of cell adhesion to fibronectin 
in mammalian cells. 
kinase predication analysis of our phosphoproteome data set was used to identified a 
target regulated by LAR. CDK1 was predominant and predicated to phosphorylate the 
majority of phosphosites. It was identified 38 putative substrates for CDK1 and 50% 
have been found in adhesome (Horton et al., 2015). CDK1 is a serine/threonine kinase 
which is a key regulator of cell cycle progression (Enserink and Kolodner, 2010). 
CDK1 activity is highly maintained and regulated, one of which is  the 
phosphorylation of Thr161 by a CDK7 (Rhind and Russell, 2012). However, 
phosphoproteome analysis showed no significant change in phosphorylation of either 
Ser164 or Thr170 on CDK7, the phosphorylation of these sites are required for activation 
of CDK7 (Larochelle et al., 2001) suggesting that LAR is regulating the activity of 
CDK1 through an alternative mechanism. 
 
 
109	
	
CDK1 has been reported to localize to focal adhesions and plays a role in the regulation 
of integrin-based cell adhesion and motility (Manes et al., 2003, Robertson et al., 
2015). Therefore, the role of CDK1 in cell adhesion was investigated. 
Phosphoproteomics and western blotting analysis revealed that LAR is required for 
the activation of CDK1. Interestingly, the regulation of focal adhesion complexes by 
LAR was through Akt and CDK1 pathway. Surprisingly, however, no significantly 
differences in the activity of FAK in both cell lines (Figure 4.1 and 4.2), suggesting 
that LAR could regulate cell adhesion in PDGF-independent manner. By using LAR 
substrate-tapping mutants, this phenotype was mainly regulated by c-Abl 
demonstrating a key role for c-Abl in mediating LAR-induced the phosphorylation of 
CDK1. Taken together, these findings reveal a novel pathway downstream of LAR 
that regulates cell adhesion in c-Abl, Akt and CDK1 dependent manner. 
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Figure 4. 9. Model showing how LAR phosphatase regulates cell adhesion via CDK1. In 
wild type MEFs, LAR dephosphorylates and inactivates c-Abl resulting in enhanced Akt and 
CDK1 signalling, leading to increased cell adhesion to extracellular matrix (ECM). In the 
absence of LAR phosphatase activity, c-Abl inhibits Akt, resulting in decreased CDK1 activity 
and decreased cell adhesion to extracellular matrix.  
Cell adhesion to ECMCell adhesion to ECM
c-Abl c-Abl
Akt
Akt
CDK1
CDK1
WT LARΔP
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CHAPTER 5 
Quantitative Phosphoproteomics Reveals a Role for Collapsin 
Response Mediator Protein 2 in PDGF-Induced Cell Migration 
 
5.1. Introduction 
Platelet Derived Growth Factor (PDGF) was first identified in platelet extracts as a 
potent mitogen for fibroblasts and endothelial cells (Waterfield et al., 1983). PDGF 
receptors are expressed by cells of mesenchymal origin and the cognate PDGF ligands 
are expressed by overlying epithelial cells indicative of paracrine signalling from 
epithelium to the underlying mesenchyme. For example, in the lung PDGFR alpha is 
expressed in the lung mesenchyme and PDGFA is expressed in the epithelium 
(Ataliotis and Mercola, 1997). This pattern is seen in multiple organs and tissues such 
as gut, kidney, gonads, somites and nervous system (Lindahl et al., 1998). These data 
show that the principle cellular targets for PDGF action are cells of mesenchymal 
origin. The PDGF signalling axis is implicated in regulation of tumour/stromal cell 
interactions (Cao, 2013, Heldin, 2013).  
PDGF-BB produced by tumours of epithelial origin acts upon adjacent connective 
tissues cells, pericytes and vascular smooth muscle cells to regulate tumour 
angiogenesis and tumour-associated fibrosis (Tsai and Yang, 2013). PDGF activated 
perivascular cells also promote metastasis via tumour-associated macrophages and act 
on tumour cells that have undergone epithelial-mesenchymal transition (EMT) to 
promote migration through the extracellular matrix (Tan et al., 2015, Y. Yang et al., 
2016). PDGF induced cell migration has been widely studied through small GTPases 
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Rac1, ERK MAPK and JNK kinases (Doanes et al., 1998, Ridley et al., 1992, Zhan et 
al., 2003). Collapsin response mediator protein-2 (CRMP2), also known as 
Dihydropyrimidinase-related protein 2; DPYSL2, is a phospho-protein that highly 
expressed in nervous system and mediate cellular processes upon external stimuli such 
as ephrins, neurotrophins and semaphorins (Uchida et al., 2005, Yamashita et al., 
2007). CRMP2 has been mainly studied in nervous system and found to regulate a 
fundamental function such as cytoskeletal remodeling, neurotransmission and axon 
guidance through interaction with microtubules (Arimura et al., 2004, Inagaki et al., 
2001, B. P. Liu and Strittmatter, 2001). Higher phosphorylated form of CRMP2 has 
been found in Alzheimer's disease suggested the contribution of CRMP2 in the 
development of this disease (Cole et al., 2007, Soutar et al., 2009). It has been 
previously demonstrated that glycogen synthase kinase-3 beta (GSK3b) can 
phosphorylates CRMP2 at Thr509, Thr514 and Ser518 thereby inhibit CRMP2 activity 
leading to microtubule depolymerisation and destabilization (Gu et al., 2000, 
Wakatsuki et al., 2011). Despite the biological significance of these activities 
relatively little is known about the downstream intracellular pathways that mediate 
these responses beyond canonical RTK signalling pathways such as PLC, AKT and 
MAPK/ERK (Heldin and Lennartsson, 2013). To gain further insight into how PDGFs 
mediate their biological effects we analysed a differential phosphoproteomics dataset 
of PDGF-stimulated mouse embryo fibroblasts (MEFs). This shows that, in MEFs, 
PDGFbR activation by PDGF-BB elicits a broad range of phosphorylation events 
mediated by downstream Ser/Thr kinases which impact on mediators of cytoskeletal 
function and cell motility. In particular, we show CRMP2 is dephosphorylated in 
response to PDGFbR activation and is required for PDGF-induced cell migration. 
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These results demonstrate an intersection between PDGF and Ephrin signalling with 
broad implications for tissue repair and tumor development. 
 
 
 
5.2. Results 
5.2.1. Global quantitative phosphoproteomics of the PDGF signalling 
in MEFs 
To identify novel PDGF downstream effectors, we determined the phosphoproteome 
of mouse embryonic fibroblasts (MEFs) in response to PDGF stimulation.	 Two 
populations of MEFs cells were SILAC-labeled by culturing them in light R0K0 or 
medium R6K4 SILAC media (Figure 5.1). Cells were left unstimulated or stimulated 
with PDGF-BB for 7 min. In total, 989 phosphosites from 611 proteins were detected 
with high localization scores (localization probability >0.75; score difference >5) in 
one or more experimental replicates. 
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Figure 5. 1. Schematic overview of experimental design. Plus (+) stimulated with PDGF 
for 7 min, minus (-) nonstimulated. 
 
 
Correlation coefficients for the peptide ratios measured across the biological and 
technical replicates, ranged from 0.77 to 0.93 (Figure 5.2A), indicating good 
biological reproducibility. Within the phosphoproteome data set, the phosphosites 
were composed of 896 (90.6%) serine, 76 (7.6%) threonine and 17 (1.7%) tyrosine 
phosphorylation sites (Figure 5.2B).  
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Figure 5. 2. The biological reproducibility and classification of phosphorylated peptides 
within phosphoproteome data set. A, Heat map of Pearson correlation coefficients and multi 
scatter plots demonstrating reproducibility between phosphoproteome of biological and 
technical replicates. B, Numbers of serine, threonine and tyrosine phosphorylation sites 
identified within our PDGF-regulated phosphoproteome data set are presented. 
 
 
Out of these, 161 phosphorylation sites showed a significant change in abundance (p 
<0.05; >1.5-fold change). A total of 116 phosphosites were upregulated and 45 
downregulated upon PDGF treatment (Figure 5.3B). Within the proteomic data set, a 
total of 703 proteins were identified in two or more biological replicates. Not 
surprisingly, there is no significantly differences in protein abundance upon 7min 
PDGF stimulation (Figure 5.3A). 
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We have observed proteins that have been shown to be involved in PDGF signalling. 
For instance, ERK1/2 are extensively studied and to be hyperphosphorylated in 
response to growth factors such as PDGF and mediated diverse physiological functions 
such as cell growth, survival, cell adhesion, migration and differentiation (Nishimoto 
and Nishida, 2006, Qi and Elion, 2005, Z. Yao and Seger, 2009). In line with many 
other studies, we found the phosphorylation of ERK1 is highly increased on Tyr205 
(ratio; 15.10) and Thr203 (ratio; 14.13). ERK2 is also hyperphosphorylated on Tyr185 
(ratio; 16.77). The phosphorylation of these sites on ERK1/2 is essential for the kinase 
activity. We have also identified increase in the phosphorylation of Bcl2-associated 
agonist of cell death (BAD) at Ser136 upon PDGF stimulation. This site is a target for 
Akt and the phosphorylation of Ser136 on BAD leads to enhance cell survival (Datta et 
al., 1997). 
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Figure 5. 3. Global phosphoproteomics and proteomics to identify novel PDGF signalling 
components. Volcano plots showing the ratio (log2 fold change) and significance (–log10 
Benjamini-Hochberg adjusted p-value) of the proteome (A) and phosphoproteome (B) in 
response to PDGF stimulation. Significantly upregulated phosphopeptides are marked in light 
brown box and the downregulated phosphopeptides are marked in pink box (adjusted p value 
<0.05; >1.5 fold-change). 
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5.2.2. Novel regulatory phosphosites regulated by PDGF 
From 161 phosphosites, we identified 110 (67%) that have not been reported as a 
PDGF regulatory sites (PhosphoSitePlus) (Hornbeck et al., 2012) and are considered 
novel (Figure 5.4). Known and novel PDGF regulatory proteins were cluster 
according to their cellular compartments (Figure 5.4). Cellular compartments analysis 
show that phosphoproteins localized in almost every part in the cell indicating the 
diversity of PDGF signalling. Within the phosphoproteomics data set, we found 
insulin receptor substrate 2 (IRS2), adaptor proteins that bind to the insulin receptor 
and regulate insulin signalling pathways. IRS2 can binds directly to insulin receptor 
(IR) leading to recruits p85-p110 heterodimer to their substrate, PI-4,5P2, at the cell 
membrane which in turn initiate PI3K/Akt signalling pathways (Hemmings and 
Restuccia, 2012, Lizcano and Alessi, 2002). We observed Ser303 on IRS2 and was 
largely upregulated upon PDGF stimulation (Figure 5.4). Interestingly, it has been 
shown that the activation of PKC isoforms, b and d by phorbol esters (PMA) or the 
induction of angiotensin II significantly induce the phosphorylation of Ser303 on IRS2 
in endothelial cells leading to inhibit insulin signalling (Park et al., 2013). Taken 
together, it has been reported that PDGF activates PKC via PLCg (Weiqun Li et al., 
1994b, Moriya et al., 1996) suggesting a novel role for PDGF as a negative regulator 
for the insulin signalling.  
The most significant upregulated response after ERK1/2 was seen for Ras-related 
protein Rab7a (Rab7a) (Figure 5.3B). Rab7a is a small GTPase protein involved in 
the regulation of endo-lysosomal trafficking (T. Wang et al., 2011). The activity of 
Rab7a is regulated by GEF (guanine-nucleotide exchange factor) and GAP (GTPase 
activation protein). It has been shown that HOPs (homotypic fusion and protein sorting 
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complex) acts as GEF for Rab7 (Wurmser et al., 2000), whereas TBC1D15 serve as 
GAP (X. H. Zhang et al., 2005). Recent study revealed that the phosphorylation of 
Rab7a on Ser72 inactivate the protein and impaired the recruitment to endosomal 
membranes and delays the transport of EGFR from early to late endosomes (Shinde 
and Maddika, 2016). It suggests that PDGFR activates an unkown kinase which in turn 
phosphorylates Ser72 on Rab7a leading to delay the EGFR trafficking indicating a 
crosstalk endocytosis signalling between two major RTKs, PDGFR and EGFR. In 
addition, we observed Slit-Robo GTPase-activating protein 3 (srGAP3), Rho GAP 
protein which involved in the development of the nervous system and has been 
reported as Robo receptor downstream protein (Y. Ma et al., 2013, Wong et al., 2001). 
We detected increase in phosphorylation of srGAP3 on Ser858. This site has previously 
been reported to be phosphorylated by protein kinase A (PKA) which in turn promotes 
GAP activity of srGAP3 toward Rac1 leading to inhibit the cytoskeletal reorganisation 
in neurons (M. Li et al., 2015b). 
Following stimulation, 45 novel PDGF-regulated phosphosites were observed to be 
significantly downregulated include Rho-associated protein kinase 2 (ROCK2; 
Ser1362), Neurofibromin (NF1; Ser2517), CLIP-associated protein 1 (CLASP1; Ser1193), 
Parva (Ser14), collapsin response mediator protein 2 (CRMP2; Thr514) and collapsin 
response mediator protein 4 (CRMP4; Thr514). These proteins are mainly involved in 
regulation of nervous system homeostasis including development, axon formation and 
growth cone guidance (Aizawa et al., 2001, Blaise et al., 2012, Charrier et al., 2003, 
M. Chen et al., 2013, Montani et al., 2009, Trovo-Marqui and Tajara, 2006), 
suggesting a common set of PDGF effectors exist in both fibroblasts and the nervous 
system and demonstrates that, in addition to the autophosphorylation and 
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phosphorylation of the PDGFR downstream proteins, PDGF can also induce the 
dephosphorylation of key downstream effectors. 
 
 
Figure 5. 4. Novel phosphosites are regulated by PDGF. All the identified Phosphopeptide 
and their sites were clustered according to their cellular component. Yellow node indicates 
downregulated phosphosites and red indicates upregulation. Sites with border are consider 
novel PDGF downstream effectors. 
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5.2.3. Functional analysis of the PDGF-regulated phosphoproteome 
GO terms analysis revealed a number of actin cytoskeleton and microtubule proteins 
are enriched in our phosphoproteome data set including LIM domain and actin-binding 
protein 1 (Lima1), Rho guanine nucleotide exchange factor 17 (Arhgef17), Band 4.1-
like protein 1 (Epb41l1) and Stathmin (Stmn1) (Figure 5.5). We observe increases in 
abundance of phosphopeptides for these proteins in response to PDGF stimulation. We 
also note the enrichment of biological processes associated with proteins involved in 
cell adhesion and migration including Reticulon-4 (Rtn4; also known as Nogo 
protein), a protein involved in the regulation of neuron development such as neurite 
growth and axon-axon adhesion and also has been shown to promotes the formation 
of endoplasmic reticulum tubules in neurons (Mathis et al., 2010, Petrinovic et al., 
2010). We have found increases in phosphorylation of Nogo at Ser105 in PDGF-
stimulated MEFs compared with non-stimulated.  
Other prominent phosphopeptide linked by GO analysis to cell adhesion is paxillin 
(PXN). PXN is an adaptor protein involved in modulation of focal adhesions and 
mediated cell adhesion pathways (Huang et al., 2003, Schaller, 2001). PDGF is known 
to regulates PXN activity by promoting the phosphorylation of Tyr118 (Abedi and 
Zachary, 1995, Panetti, 2002). We have not identified this site on PXN in our 
phosphoproteomics data set, but instead we identified the phosphorylation of Ser83. It 
has been reported that p38MAPK and ERK1/2 can phosphorylate PXN at Ser83 to 
regulate neurite extension and chemotaxis in neurons (Huang et al., 2004, S. H. Lee et 
al., 2012).  
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Figure 5. 5. GO terms analysis of the PDGF-regulated phosphoproteome. Proteins 
containing the 161 PDGF regulated phosphosites were analyzed in DAVID to identify 
enriched GO Terms. Biological processes are visualised using REVIGO as a Tree map and 
indicated by color key. The size of the box is indicated the number of genes in that category. 
 
 
KEGG pathway analysis of PDGF-regulated proteins revealed enrichment of 
signalling pathways implicated in cell migration including focal adhesions, regulation 
of actin cytoskeleton, adherens junctions and transendothelial cell migration (Figure 
5.6A). In addition, KEGG analysis of the dataset also identified neurotrophin 
signalling and axon guidance as PDGF-regulated processes (Figure 5.6A). To identify 
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which kinases are activated upon PDGF stimulation, we used the Kinase Enrichment 
Analysis (KEA) (Lachmann and Ma'ayan, 2009). KEA is a web-based software tool 
for the predication of kinase-substrate interactions and linking mammalian proteins 
with the upstream kinases that potentially phosphorylate them. KEA analysis revealed 
a significant enrichment of kinases for ribosomal protein S6 kinase (RSK2) (Figure 
5.6B). It has been reported that RSK2 promotes cell motility and invasion by mediating 
the activity of integrin and actin cytoskeleton rearrangement (Gawecka et al., 2012, 
Kang et al., 2010, C. J. Lee et al., 2015, Sulzmaier and Ramos, 2013). RSK2 can also 
promote migration in epithelial cells through FGFR2-p38 kinase axis pathway 
(Czaplinska et al., 2014). KEA analysis also identified over-presented of other kinases 
include dual specificity mitogen-activated protein kinase kinase (MEK1) and c-Jun N-
terminal kinase (JNK1) (Figure 5.6B). The activity of both kinases are known to be 
regulated by growth factors such as PDGF and they involved in regulation of many 
cellular functions including cell migration (Westerlund et al., 2011, Zhan et al., 2003). 
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Figure 5. 6. PDGF regulated distinct signalling pathways. A, KEGG annotated pathways 
that were enriched in PDGF-regulated phosphoproteome. B, Kinase enrichment analysis of 
the PDGF regulated phosphopeptides. Network shows the enriched upstream kinases and node 
size corresponds to kinase enrichment. 
 
 
 
	
	
	
125	
	
5.2.4. CRMP2 is a novel PDGF-downstream protein 
CRMP2 has been widely studied in the nervous system as a mediator of neuronal 
polarity, growth and axonal guidance (Arimura et al., 2004, J. P. Ip et al., 2014). We 
were able to detect the phosphorylation of CRMP2 at the highly-conserved site 
(Thr514) in our screen and it was significantly downregulated upon PDGF stimulation 
(Figure 5.7A and B). To confirm that PDGF controls CRMP2 phosphorylation, we 
used phosphospecific antibody recognize Thr514. Western blotting showed that 
phosphorylation of CRMP2 at Thr514 was downregulated following PDGF stimulation 
compared with non-stimulated cells (Figure 5.7C). These data clearly show that 
PDGF induces the activity of CRMP2 by promoting dephosphorylation at Thr514. 
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Figure 5. 7. CRMP2 is a novel PDGF effector. A, Tandem mass spectrum of CRMP2 
phosphopeptide. B, schematic structure of CRMP2 shows the highly conserved motif around 
Thr514. C, MEFs were stimulated with 20 ng/mL PDGF for 7 min. CRMP2, CRMP2 Thr514, 
ERK1/2, ERK 1/2 Thr202/Tyr204 and Alix in whole cell lysates were analyzed by Western 
blotting. D, Western blots were quantified and ratios of pCRMP to CRMP2 were plotted and 
statistical significance was calculated using Student’s t-test (**, p<0.01). 
 
 
Next we test if PDGF induces one of the Ser/Thr phosphatase in order to 
dephosphorylate CRMP2 for optimum activity. It has been previously shown that PP1 
or PP2A can dephosphorylate CRMP2 at Ser518, Thr 514 or Thr509 (Cole et al., 2008, 
Zhu et al., 2010).  We tested the effect of okadaic acid on CRMP2 phosphorylation at 
Thr514 upon PDGF stimulation in MEFs. PP2A can be inhibited at low concentration 
(lower than 1µM), whereas the high concentration inhibits PP1 (Cohen et al., 1990, 
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Cohen et al., 1989). Western blot analysis showed no significant changes of okadaic 
acid at (0.01 µM or 1 µM) concentration compare to control (Figure 5.8). However, 
the higher concentration (1.5 µM) restored the phosphorylation of CRMP2 at Thr514 
in response to PDGF stimulation (Figure 5.8). Together, these observations suggest 
that PDGF may promotes the PP1 to dephosphorylate CRMP2 at Thr514. 
 
 
Figure 5. 8. PP1 dephosphorylates CRMP2 Thr514 in response to PDGF stimulation. A, 
MEFs were incubated with either DMSO or okadaic acid (0.01 µM, 1 µM or 1.5 µM) for 30 
min prior stimulation with 20ng/mL PDGF for 7 min. CRMP2, CRMP2 Thr514, total 
phospho-threonine and Alix in whole cell lysates were analyzed by Western blotting. B, 
Western blots were quantified and ratios of pCRMP to CRMP2 were plotted and statistical 
significance was calculated using two-way ANOVA with Sidak’s test (* P<0.05). 
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5.2.5. CRMP2 knockdown inhibits cell migration in MEFs 
CRMP2 widely studied in nervous system and has been reported to regulate neuronal 
migration (J. P. Ip et al., 2014). For instance, α2-chimaerin mediates neuronal 
migration by upregulation of CRMP2 activity and the depletion of α2-chimaerin leads 
to disrupt migration in neurons (J. P. Ip et al., 2012). In addition, CRMP2 knockdown 
showed trapped neurons in intermediate	cortical zone and resulted in morphological 
changes such as reduced in neuron processes (J. P. Ip et al., 2012). CRMP2 knockdown 
can also reduce migration of the T lymphocytes in virus-induced neuronal 
inflammation (Varrin-Doyer et al., 2012). However, the regulation of cell migration 
by CRMP2 outside nervous system has not been studied. Therefore, we asked whether 
CRMP2 regulates migration in fibroblast in response to PDGF stimulation. To test 
this, we used siRNA to knockdown CRMP2 and examined the consequences of 
CRMP2 depletion in a standard in vitro scratch wound healing assay. CRMP2 
knockdown resulted in significant reduction in cell migration in response to PDGF 
stimulation (Figure 5.9). Here we have identified CRMP2 as a novel PDGF 
downstream effector and required for PDGF-induced cell migration in fibroblast.  
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Figure 5. 9. PDGF-induced cell migration through CRMP2. A, MEFs were transiently 
transfected with CRMP2 siRNA (siCRMP2) or non-silencing control (NSC) prior wound 
healing assay. B, Cells were then wounded using an automated scratch maker and images of 
five separate wounds were taken at 0, 10, 20, 30, 40, 50, and 60 h post wounding using the 
IncuCyte ZOOM imaging system. C, Statistical significance was calculated using two-way 
ANOVA with Sidak’s test (**P<0.01, ***P<0.001). 
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5.3. Discussion 
PDGF ligands and their cognate receptors are expressed in a wide range of tissues 
during embryonic development (Hoch and Soriano, 2003). Extensive and detailed 
genetic studies of PDGF and PDGFR function in the mouse confirms that PDGF 
signalling from epithelial cells via PDGFRs is absolutely required for the expansion 
and migration of specific mesenchymal cell populations (Betsholtz, 2004).  For 
example, in the kidney PDGF signalling is required both for the multiplication of 
mesangial cell precursors and their migration into the glomerular space (Lindahl et al., 
1998). In the lung PDGF is required for the expansion of myofibroblasts and their 
migration along the alveolar epithelium during lung morphogenesis (Bostrom et al., 
1996). In the central nervous system (CNS) oligodendrocyte precursor (O2A) cells 
require PDGF signalling both for population expansion and migration through the 
spinal cord (Calver et al., 1998).  
PDGF signalling also has significant functions in adult tissue homeostasis and 
regeneration acting on cells of mesenchymal origin. PDGF is an established mitogen 
and chemoattractant for mesenchymal derived cells in vitro and has been studied for 
its ability to promote wound healing through promoting the migration, proliferation 
and extracellular matrix deposition by fibroblasts (Siegbahn et al., 1990, Werner and 
Grose, 2003). However, PDGFbR signalling networks initiated by PDGF other than 
PI3K, MAPK and PLC remain to be well established. Therefore, we have established 
the first global phosphoproteomics of the PDGF-dependent signalling network in 
fibroblasts. We have identified 989 phosphosites from 611 proteins in our screen. Out 
of these, 116 phosphopeptides were significantly upregulated. These data supported 
the notion that PDGF induction initiates signalling cascade by promoting 
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phosphorylation and autophosphorylation of the downstream molecules. 
Phosphoproteomics analysis also revealed novel 110 phosphosites that were regulated 
by PDGF. For example, Rab7, one of the key small GTPase protein which involved in 
the regulation of endocytosis and trafficking (T. Wang et al., 2011). 
Dephosphorylation of Ser72 on Rab7 by PTEN is essential for the protein activity and 
the transport of the protein target from early to late endosome for protein degradation 
(Shinde and Maddika, 2016). Our data showed that PDGF is highly induced the 
phosphorylation of Rab7 at Ser72 suggesting a role for PDGFbR in regulation of 
endocytosis. The explanation for this is that either PDGFbR directly phosphorylates 
Rab7 or indirectly by suppresses PTEN activity which in turn inducing the 
phosphorylation.  
Interestingly, we were able to detected 45 phosphopeptides that were significantly 
downregulated. Therefore, our findings not only supported that PDGF promotes 
downstream proteins phosphorylation, but also showed that PDGF can induces 
dephosphorylation of crucial downstream proteins such as CRMP2 and CLASP1.  
CLASP1 is microtubule protein involved in stabilization of microtubules dynamics, 
cell motility and acts as a downstream for Abl protein tyrosine kinase mediating axon 
guidance (Akhmanova et al., 2001, H. Lee et al., 2004). Phosphoproteomic and 
western blotting analysis indicated that PDGF mediates dephosphorylation of CRMP2 
at Thr514. CRMP2 is highly expressed in neurons and has been reported to involved in 
regulation of many cellular functions in nervous system. The KEGG pathways analysis 
revealed enrichment of pathways that have not been linked with PDGF including 
insulin signalling, axon guidance, endometrial cancer and neurotrophin signalling 
pathway. Taken together, our phosphoproteomics screen revealed an evidence that 
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PDGF and PDGFbR are mediating neuronal signalling and showed the importance of 
PDGF signalling with broad implications for physiological homeostasis and 
development. 
The downregulated phosphopeptides in our data set support the notion that PDGF can 
also regulate the activity of protein phosphatase. We have shown that inhibition of 
protein phosphatase 1 (PP1) by okadaic acid restored the phosphorylation of CRMP2 
at Thr514. Interestingly, CRMP2 cannot dephosphorylated in non-stimulated cells 
indicating that PDGF is essential for the activity of PP1. CRMP2 phosphorylation is 
controlled by GSK3b to deactivate CRMP2 in neurons which in turn leading to 
destabilizes microtubules. PDGF has been previously shown to induce cell migration 
via canonical pathways such as Rac, MAPK/ERK and JNK. Therefore, we examined 
whether PDGF regulates cell migration through novel downstream protein, CRMP2. 
We have shown that CRMP2 knockdown in fibroblasts significantly reduced cell 
migration in response to PDGF stimulation. This data clearly indicates CRMP2 
induced cell migration outside nervous system in PDGF-dependent manner (Figure 
5.10). It will be interesting to characterize whether the many other novel PDGF 
downstream proteins identified in this study play an important role in PDGFbR 
signalling pathways in health and disease. 
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Figure 5. 10. Suggested model showing how PDGF regulates cell migration through CRMP2. 
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CHAPTER 6 
	
Quantitative Proteomics Identifies a Role for LAR in 
Regulation of Mitochondrial Respiration 
 
6. 1. Introduction 
A key function of mitochondria is the production of energy (ATP) through a process 
called oxidative phosphorylation (OXPHOS) (Chandra and Singh, 2011). OXPHOS 
consists of ATP synthase proteins (complex V) and four respiratory chain complexes 
(I–IV) with all complexes located in the mitochondrial inner membrane (Poyton and 
McEwen, 1996). The OXPHOS system is a process involved in the transport of 
electrons generated by NADH (reduced nicotinamide adenine dinucleotide) through a 
number of carrier molecules called the electron transport chain or respiratory 
complexes (complexes I-V) (Smeitink et al., 2001). The passing of these electrons 
through the respiratory complexes leads to energy release, which can be used by ATP 
synthase proteins (complex V) to generate ATP from ADP (adenosine 5′-diphosphate) 
and phosphate (Poyton and McEwen, 1996, Smeitink et al., 2001, Zorov et al., 2014). 
Complex I (NADH-ubiquinone oxidoreductase) is the largest complex and contains 
more than 42 proteins (Brandt, 1997, Skehel et al., 1998). This complex is the main 
source for the production of reactive oxygen species (ROS) in the mitochondria 
(Smeitink et al., 2001). It has been reported that mutations in complex I subunits are 
responsible for neurological disorders such as Parkinson's disease (Gorman et al., 
2016, Pagliarini et al., 2008, Perry et al., 1982, Spencer et al., 1998). Complex II 
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(succinate-ubiquinone oxidoreductase), also known as succinate dehydrogenase 
(SDH), are enzymes that oxidize succinate to fumarate during the Krebs cycle and 
electron respiratory chain (Yankovskaya et al., 2003). In complex III (ubiquinol-
cytochrome c oxidoreductase), the electrons are passed from ubiquinol to cytochrome 
c by a mechanism called the Q-cycle, which in turn releases protons into the 
mitochondrial intermembrane space (F. L. Muller et al., 2004, Z. Zhang et al., 1998). 
Ultimately, enzymes in complex IV (cytochrome c oxidase) receive the electrons from 
complex III and convert them into water molecules leading to a membrane potential 
that can be used by complex V (ATP synthase) to produce ATP from ADP (Poyton 
and McEwen, 1996, Smeitink et al., 2001, Zorov et al., 2014).  
In this chapter, the proteomic dataset was further analysed in order to identify protein 
expression regulated by LAR. Within the proteomic data set, a total of 2939 proteins 
were identified. Of these, 147 proteins showed a significant change in abundance in 
LARDP MEFs compared with the WT MEFs, suggesting a role for LAR in regulation 
of protein turnover. GO term analysis revealed enrichment of metabolic processes 
including the oxidation-reduction process. In addition, higher mitochondrial 
respiration was observed in LARDP MEFs compared to WT suggesting that LAR 
suppresses mitochondrial respiration by regulating protein turnover.  
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6.2. Results 
6.2.1. Quantitative proteomics of LAR-regulated protein expression 
For the proteomics analysis, 5 µg of light, medium, and heavy lysates from each 
experiment were mixed, run on SDS-PAGE gel and Coomassie stained (Figure 6.1). 
Each lane was cut into 10 bands and the protein digestion was carried out using In-gel 
digestion approach (Shevchenko et al., 2006). Within our proteome data set, a total of 
1491 proteins were identified in at least one biological replicates and 1150 proteins 
were associated with quantitation data in two or more biological replicates. Of these, 
147 proteins showed a significant change in abundance (p<0.05; >1.5-fold change) in 
the LARDP cells compared with WT. Interestingly, 47 proteins were upregulated and 
100 proteins were downregulated (Figure 6.2). This is a significant finding as 13% of 
the quantified proteome was changed because of the absence of LAR phosphatase 
activity suggesting that LAR may be involved in regulating protein turnover. 
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Figure 6. 1. Global proteomics to determine LAR-regulated protein expression. 
Schematic overview of experimental design. 5 µg of WT MEFs (SILAC light, medium, and 
heavy) or LARDP MEFs (SILAC light, medium, and heavy) lysates from each biological 
replicate (including the reverse labelling experiment) were mixed, run on SDS-PAGE gel. 
Each lane was cut into 10 bands and the protein digestion was carried out using In-gel digestion 
approach for mass spectrometry based-proteomic analysis. The identification and 
quantification was carried out using MaxQuant software. (+) with PDGF-BB, (-) without 
PDGF-BB. 
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Figure 6. 2. Global proteomics to determine the contribution of LAR to protein 
expression. Volcano plots showing the ratio (log2 fold change) and significance (–log10 
Benjamini-Hochberg adjusted p-value) of the proteome data set (adjusted p value <0.05; >1.5 
fold-change). The upregulated and downregulated proteins are highlighted.  
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6.2.2. Functional analysis of the LAR-regulated proteome 
KEGG pathway analysis of LAR-regulated protein levels revealed enrichment of 
pathways implicated in metabolic pathways including pyruvate metabolism, fatty acid 
metabolism and glutathione metabolism (Figure 6.3). These findings demonstrated 
that LAR may be involved in regulation of metabolic processes. In addition, KEGG 
analysis of the proteome dataset also identified focal adhesion and regulation of actin 
cytoskeleton as LAR-regulated processes.  
 
 
Figure 6. 3. Over-represented pathways of the LAR-regulated proteome. Significantly 
changed proteome data set were analysed in DAVID to identify enriched KEGG pathways. 
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Gene Ontology analysis of the proteome regulated by LAR revealed a number of 
enriched GO terms. All the significantly changed proteins are clustered according to 
their functional keywords as indicated in Figure 6.4. The dominant enriched 
functional group was associated with metabolic processes and cytoskeletal 
organisation. Metabolism proteins that were enriched in our proteome data set 
included: Alpha-mannosidase 2 (Man2a1), a protein involved in the protein 
glycosylation pathway (Moremen and Nairn, 2014); Adenine phosphoribosyl 
transferase (Aprt) as enzyme that regulate AMP synthesizes from adenine (Sassone-
Corsi, 2012); Adenylate kinase 1 (Ak1), a kinase that play a key role in maintaining 
cellular energy homeostasis (Noma, 2005). We observed an increase in abundance of 
these proteins in LARDP cells compared with WT.  
We also noted the enrichment of biological process for proteins associated with 
oxidation-reduction process including Aldose reductase (Akr1b1), Succinate 
dehydrogenase flavoprotein, mitochondrial (Sdha) and Sodium/potassium-
transporting ATPase subunit alpha-1 (Atp1a1) suggesting a role for LAR in regulation 
of mitochondrial respiration.  
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Figure 6. 4. LAR regulated distinct metabolic processes. Proteins were clustered according 
to their functional keywords. Large node size indicates that the protein was up-regulated in 
LARDP cells and small node size indicates down-regulation. 
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6.2.3. Deletion of LAR phosphatase domains increase mitochondrial 
respiration 
Having identified proteins that have a role in regulation of redox processes and 
mitochondrial respiration, we decided to study whether LAR was involved in the 
regulation of mitochondrial respiration. Mitochondrial respiration was analysed using 
a Seahorse XF Analyzer (Salabei et al., 2014). WT and LARDP cells were either grown 
in complete or starvation media overnight and the basal respiration, ATP production, 
maximal respiration and non-mitochondrial respiration measured by serial injecting of 
oligomycin (Oligo), carbonyl cyanide p-trifluoromethoxy-phenylhydrazone (FCCP) 
and rotenone/ antimycin A (Rot/AA). Oligo inhibits complex V, whereas FCCP 
enhance the production of ATP. Rotenone and antimycin A can be used to inhibit 
complex I and III (Salabei et al., 2014).   
In complete medium, both basal and maximal respiration rates were significantly 
higher in LARDP cells compared with WT (Figure 6.5).  
In starvation media, mitochondrial respiration was significantly reduced in WT cells 
compared with LARDP cells. Interestingly, mitochondrial respiration was higher in 
LARDP cells compared to WT cells and even higher when compared with LARDP 
cells that grown in complete media (Figure 6.6).  
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Figure 6. 5. Role of LAR on mitochondrial respiration. A, the profile mitochondrial 
respiration test in WT and LARDP cells for the measurement of basal respiration (B) and 
maximal respiration (C). WT and LARDP cells were seeded to 40,000 cells/ well in XF24 cell 
culture plates and incubate in complete media for 24 h prior to the assays. Oxygen 
consumption rate (OCR) was measured under basal state followed by the sequential injection 
of oligo (1 µM), FCCP (1 µM), and rotenone/ antimycin A (0.5 µM) to determine the ATP 
production and maximal respiration. Statistical significance was calculated using Student’s t-
test (***, p<0.001). 
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Figure 6. 6. Role of LAR on mitochondrial respiration. A, the profile mitochondrial 
respiration test in WT and LARDP cells for the measurement of basal respiration (B) and 
maximal respiration (C). WT and LARDP cells were seeded to 40,000 cells/well in XF24 cell 
culture plates and incubate in starvation media for 24 h prior to the assays. Oxygen 
consumption rate (OCR) was measured under basal state followed by the sequential injection 
of oligo (1 µM), FCCP (1 µM), and rotenone/ antimycin A (0.5 µM) to determine the ATP 
production and maximal respiration. Statistical significance was calculated using Student’s t-
test (***, p<0.001). 
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6.2.4. Increased expression of succinate dehydrogenase protein in 
LARDP cells 
Since the XF analysis revealed higher mitochondrial respiration in LARDP cells 
compared with WT in either complete or starvation media (Figure 6.5 and 6.6), the 
expression of proteins involved in the regulation of the OXPHOS system was further 
investigated in WT and LARDP MEFs. Immunoblotting analysis was carried out using 
an antibody that recognizes one protein from each of the OXPHOS complexes 
including NADH dehydrogenase alpha subcomplex subunit 8 (Ndufa8) from complex 
I, succinate dehydrogenase [ubiquinone] iron-sulfur subunit b (Sdhb) from complex 
II, cytochrome b-c1 complex subunit 2 (Uqcrc2) from complex III, cytochrome c 
oxidase subunit 1 (Mtco1) from complex IV and ATP synthase subunit alpha 
(ATP5A1) from complex V. All the subunits showed no significant difference in 
expression, except succinate Sdhb from complex II which significantly increased in 
expression in LARDP compared with WT cells (Figure 6.7). 
146	
	
 
Figure 6. 7. Up-regulation of the mitochondrial SDHB expression in LARDP MEFs. A, 
Expression of the proteins involved in oxidative phosphorylation was analysed using an 
OXPHOS cocktail antibody and Alix was used to control for loading. B, Results from western 
blotting analysis (n=3) were quantified and ratios of OXPHOS to Alix plotted. Statistical 
significance was calculated using two-way ANOVA with Sidak’s test (** p<0.01). 
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6.3. Discussion 
Mitochondria are involved in regulation of multiple cellular functions, signal 
transduction and metabolic pathways (Chandra and Singh, 2011, Saraste, 1999). 
Mitochondria is mainly involved in the production of energy through oxidative 
phosphorylation (OXPHOS) system (Smeitink et al., 2001). In this chapter, the 
proteomics datasets were further analysed to identify and characterize protein 
expression regulated by LAR. A total of 1491 proteins were identified in at least one 
biological replicate and 1150 proteins were associated with quantitation data in two or 
more biological replicates. Of these, 147 proteins showed a significant change in 
abundance. Interestingly, 47 proteins were significantly upregulated and 100 proteins 
were downregulated suggesting that LAR may be involved in regulation of protein 
turnover since 13% of the quantified proteome data was changed due to the absence 
of LAR phosphatase activity.  
KEGG pathway analysis of the significantly changed proteins revealed over-
representation of several metabolic pathways, demonstrating that LAR may be 
involved in regulation of metabolic processes. In addition, GO term analysis identified 
many proteins involved in regulation of metabolic processes such as Adenylate kinase 
1 (Ak1), a kinase that has a key role in maintaining cellular energy homeostasis by 
catalyzes adenine nucleotides (Noma, 2005). It has been shown that Ak1 knockout 
mice have significantly reduced ATP levels in myocardial cells leading to myocardial 
dysfunction (Dzeja et al., 2007) suggesting a key role for Ak1 in controlling the 
myocardial energy state and homeostasis. Upregulation of Ak1 was observed in 
LARDP cells compared with WT. This is suggesting that LAR could suppresses the 
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expression of this protein at either protein or mRNA level and thus modulate energetic 
homeostasis.  
Since the bioinformatics analysis of the proteome data set identified proteins that have 
a role in regulation of redox processes and mitochondrial respiration, mitochondrial 
respiration was investigated to determine whether LAR has a role in this process. 
Seahorse XF analysis clearly showed a significant increase in the basal and maximal 
mitochondrial respiration in LARDP MEFs compared to WT. Interestingly, serum 
starvation causes suppression of respiration in WT cells. However, starvation did not 
affect the respiration of LARDP cells. Instead, the basal and maximal respiration was 
even higher when compared with LARDP cells grown in complete media. This 
demonstrates that LAR phosphatase activity has a negative effect on mitochondrial 
activity and this is could be via suppression of mitochondrial proteins expression.  
Mitochondria are mainly involved in the production of ATP and this function is 
regulated by a process called OXPHOS (Chandra and Singh, 2011, Murphy, 2009). 
OXPHOS is consisted of ATP synthase proteins (complex V) and four respiratory 
chain complexes (I–IV) (Poyton and McEwen, 1996). In order to identify if LAR 
controls the protein levels in these complexes, western blotting analysis was carried 
out using an antibody that recognized one protein from each of the OXPHOS 
complexes. Upregulation in one of the main proteins in complex II (Sdhb) was 
observed in LARDP cells compared with WT. Sdhb is involved in the oxidization of 
succinate to fumarate during the Krebs cycle (Yankovskaya et al., 2003). In addition, 
Sdhb was identified as a tumor suppressor (Bayley et al., 2006, Benn et al., 2003, 
Gimenez-Roqueplo et al., 2002). Sdhb overexpression has been linked to inhibition of 
cell proliferation, invasion and induced apoptosis in human ovarian cancer through the 
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suppression of AMPK-HIF-1α pathway (L. Chen et al., 2014).  Taken together, these 
data suggest that LAR could decrease mitochondrial respiration through suppression 
of Sdhb.  
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CHAPTER 7 
LAR Protein Tyrosine Phosphatase Enhances PDGFβR 
Signalling by Suppression of GRK2 Activity 
 
7.1. Introduction	
Many activities that occur in cells such as growth, survival, motility, proliferation and 
differentiation, are regulated by growth factors such a PDGF. PDGF is a stimulator 
of cellular processes in many cells including fibroblasts, smooth muscle cells, neurons 
and endothelial cells (Ataliotis and Mercola, 1997). Several protein tyrosine 
phosphatases (PTPs), including Shp-1, Shp-2 and TC-PTP, are able to 
dephosphorylate tyrosine residues on PDGFβR, which in turn deactivates the receptor 
kinase activity. It has been previously discovered that, unlike the other protein 
tyrosine phosphatases, leukocyte common antigen related (LAR) can control 
PDGFβR activity by enhancing PDGFβR phosphorylation (Zheng et al., 2011).  
LAR is widely expressed in human tissues such as brain, heart and bladder (Johnson 
et al., 2006). Several studies have found that LAR plays an important role in 
regulation of cell signalling and regulates cellular functions such as neuronal growth 
and neuronal regeneration (Sethi et al., 2010). Several phenotypic disorders have been 
recognized in LAR-deficient mice including defects in the development of mammary 
glands, neuron degeneration, axon guidance defects, reduction in the rate of hepatic 
glucose production, diabetes and cancer (Andersen et al., 2001, Kanakaraj et al., 
1991, Sethi et al., 2010, Van Lieshout et al., 2001).  
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G protein-coupled receptor kinase 2 (GRK2), also called β-adrenergic receptor 
kinase-1, is a serine/ threonine kinase which play an important role in the regulation 
of cellular signalling (Black et al., 2016). GRK2 phosphorylates PDGFβR leading to 
a reduction in receptor autophosphorylation and desensitization (J. H. Wu et al., 
2005). Protein kinase C (PKC) phosphorylates and activates GRK2 promoting 
translocation of GRK2 to the cell membrane (Krasel et al., 2001, Winstel et al., 1996). 
Furthermore, Src-mediated tyrosine phosphorylation of GRK2 promotes kinase 
activity (Penela et al., 2001, Sarnago et al., 1999). ERK1 can phosphorylate GRK2 at 
Ser670 inhibiting its kinase activity (Elorza et al., 2000, Pitcher et al., 1999). GRK2 
overexpression has been linked to many pathological conditions such as heart failure 
and hypertension (Elorza et al., 2003). GRK2 overexpression has also been shown to 
decrease proliferation of smooth muscle cells (Aragay et al., 1998). More recently, 
investigators have revealed that overexpression of GRK2 increases reactive oxygen 
species (ROS) production in cardiac myocytes by promoting the expression of 
NADPH oxidase 4 (Nox4) leading to heart failure (Theccanat et al., 2016).  
Na+/H+ exchanger regulatory factors NHERF1 (also called EBP50) and NHERF2 
(also known as E3KARP) are adaptor proteins which can bind with cytoskeletal 
proteins ezrin, radixin, moesin, and merlin comprised through their PDZ domains 
(Dunn and Ferguson, 2015, Karthikeyan et al., 2001, Voltz et al., 2001). NHERF1 is 
expressed in restricted areas such as kidney, intestine, prostate and mammary tissue, 
while NHERF2 is widely expressed in many cells (Weinman et al., 1995). NHERF1 
and NHERF2 form homodimers and heterodimers with each other via their PDZ 
domains and with other PDZ-containing proteins creating a membrane scaffold that 
can bind transmembrane or intracellular proteins such as transporters, ion channels 
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and signal transduction molecules (Fouassier et al., 2000, Shenolikar et al., 2001, 
Weinman et al., 2000). NHERF1 has been shown to bind to PDGFβR via its PDZ1 
domain and to potentiate receptor autophosphorylation and downstream signalling 
activity (Maudsley et al., 2000). Another study reported that NHERF2 also binds to 
the c-terminal of PDGFβR enhancing ERK and Akt signalling (Jung Kang et al., 
2004). In contrast, depletion of NHERF1 or NHERF2 in MEFs enhances PDGFR 
signalling suggesting a different role for NHERFs whereby they promote the 
recruitment of the phosphoinositide phosphatase (PTEN) to the PDGFR, which in 
turn attenuates receptor signalling (Takahashi et al., 2006). In 2004, Hildreth and co-
workers published a paper in which they identified that GRK2 can phosphorylate 
PDGFβR on Ser1104, preventing the association of Na+/H+ exchanger regulatory factor 
1 (NHERF1) with the receptor, and hence decreased receptor signalling (Hildreth et 
al., 2004). 
Here, it was determined that LAR is required for PDGFβR activation. We have also 
identified GRK2 as a part of a negative feedback loop regulating PDGFβR signalling. 
Therefore, this suggests a signalling pathway connecting LAR and GRK2 to the 
regulation of PDGF signalling. 
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7.2. Results 
7.2.1. LAR positively regulates PDGFβR tyrosine phosphorylation 
Many protein tyrosine phosphatases (PTPs) are known to modulate PDGFβR by 
dephosphorylating tyrosine residues on the receptor. For example, PTP1B 
dephosphorylates Tyr579 residue on PDGFβR preventing Src and Shc binding, thereby 
terminating the signalling cascade (Ekman et al., 2002, Persson et al., 2004). 
However, PTPs, such as SHP-2, can also promote PDGFβR signalling (Ekman et al., 
2002, Lechleider et al., 1993). LAR dephosphorylates receptor tyrosine kinases such 
as the insulin receptor and decreases their activity (Tsujikawa et al., 2001).  
To examine whether LAR is involved in the regulation of PDGFβR activity, total 
tyrosine phosphorylation of PDGFβR was analysed in WT and LARΔP MEFs. We 
found a significant reduction in tyrosine phosphorylation in LARΔP cells compared 
with WT cells Figure 7.1). These data indicating that LAR phosphatase domains are 
required for PDGFβR tyrosine phosphorylation. 
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Figure 7. 1. Deletion of LAR phosphatase domains reduces PDGFβR tyrosine 
phosphorylation. A, WT and LARΔP cells were stimulated with 20 ng/mL PDGF-BB for 
indicated times. PDGFβR was immunoprecipitated using a PDGFβR-specific antibody and 
immunoprecipitates were immunoblotted with either PDGFβR or total phosphotyrosine 
(PY99) antibodies. To control for expression levels, whole cell lysates (WCL) were 
immunoblotted with Alix antibody. B, Western blots (n=3) were quantified and ratios of 
pPDGFβR to PDGFβR were plotted over time. Statistical significance was calculated using 
two-way ANOVA with Sidak’s test (*** p<0.001; * p<0.05). 
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7.2.2. GRK2 phosphorylation is regulated by LAR 
Having identified that LAR potentiates PDGFβR tyrosine phosphorylation, we 
further investigated the underling mechanism on how LAR regulates PDGFβR. It has 
been previously shown that serine phosphorylation of the receptor can lead to reduced 
receptor tyrosine autophosphorylation and kinase activity. GRK2 regulates PDGFβR 
by mediating serine phosphorylation leading to receptor desensitization and reduces 
receptor autophosphorylation (J. H. Wu et al., 2005). To examine whether LAR 
regulates GRK2 activity, the tyrosine phosphorylation of GRK2 was investigated. We 
observed higher GRK2 phosphorylation in LARΔP cells compared with WT (Figure 
7.2).  
 
 
Figure 7. 2. Higher GRK2 tyrosine phosphorylation in LARΔP cells. A, WT and LARΔP 
cells were stimulated with 20 ng/mL PDGF-BB for 7 min. GRK2 was immunoprecipitated 
and immunoblotted with either GRK2 or total phosphotyrosine (PY99) antibodies. To control 
for expression levels, whole cell lysates (WCL) were immunoblotted with Alix antibody. B, 
Western blots (n=3) were quantified and ratios of PY99 to GRK2 were plotted. Statistical 
significance was calculated using two-way ANOVA with Sidak’s test (** p<0.01). 
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In collaboration with a Masters student (Assel Bektassova) in our lab, I carried out a 
quantitative SILAC proteomics study to characterise phosphorylation of GRK2 as 
well as identify interacting proteins following PDGF stimulation (Figure 7.3A). WT 
and LARΔP MEFs were grown in either ‘Heavy’ R10K8 or ‘Light’ R0K0 SILAC 
media, respectively. Cells were stimulated with PDGF for 15 min prior to 
immunoprecipitation of GRK2 and subsequent mass spectrometric analysis. Within 
our quantitative proteomics data, we identified a 2-fold increase in the 
phosphorylation of Ser670 on GRK2 in WT cells compared to LARΔP cells (Figure 
7.3B). This suggests that LAR is involved in the regulation of GRK2 activity, since 
the phosphorylation of this residue leads to inhibition of kinase activity (Elorza et al., 
2000, Pitcher et al., 1999). 
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Figure 7. 3. GRK2 is regulated by LAR. A, Schematic overview of experimental design. B, 
Tandem mass spectrum of GRK2 phosphopeptide around Ser670. 
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7.2.3. GRK2 depletion rescued the activity of PDGFβR downstream 
signalling in LARΔP MEFs 
Next we examined whether GRK2 is involved in the regulation of PDGFβR signalling 
by LAR. Consistent with previous data, the activity of ERK1/2 and Akt were much 
lower in LARΔP than WT cells demonstrating that LAR activity is required for the 
PDGF induced downstream signalling pathways (Figure 7.4). To examine if the 
higher activity of GRK2 in LARΔP cells is responsible for the reduced PDGFβR 
signalling, RNA interference was used to knockdown GRK2 in LARΔP MEFs and 
the activity of PDGFβR downstream proteins were analysed by western blotting. 
GRK2 depletion in LARΔP MEFs partially restored the phosphorylation of ERK1/2 
and Akt suggesting that LAR could positively regulate PDGFβR activity via GRK2 
(Figure 7.4). 
 
 
Figure 7. 4. Knockdown GRK2 restored the activity of PDGFβR signalling. LARΔP 
MEFs were transiently transfected with siRNA oligonucleotides targeted against GRK2 or 
with control non-silencing oligonucleotides (NSC). At 48 h after transfection, cells were 
stimulated with 20ng/mL PDGF-BB for indicated time periods. ERK1/2, ERK 1/2 
Thr202/Tyr204, Akt, Akt Thr308 and Alix in whole cell lysates were analyzed by Western 
blotting (n=3). 
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7.2.4. Increased interaction of NHERF2 and PDGFβR in WT MEFs 
NHERF2 is known to interact with, and regulate the activity of, PDGFβR. Therefore, 
to test if LAR controls the interaction of NHERF2 with PDGFβR, WT and LARΔP 
cells were transfected with both NHERF2 and PDGFβR plasmids. We found more 
NHERF2 associated with PDGFβR in WT cells compared with LARΔP MEFs 
following PDGF stimulation (Figure 7.5). These data suggest a novel role for LAR 
in regulation of PDGF signalling via GRK2.  
 
 
 
Figure 7. 5. LAR is required for the interaction of NHERF2 with PDGFβR. FLAG-tagged 
PDGFβR along with NHERF2 were co-expressed in either WT or LARDP cells. PDGFβR was 
immunoprecipitated using anti-FLAG beads and immunoprecipitates were immunoblotted 
with either PDGFβR or NHERF2 antibodies. To control for expression levels, whole cell 
lysates (WCL) were immunoblotted with Alix antibody (n=1).
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7.3. Discussion 
PDGF is involved in regulation of many cellular function including growth, survival, 
motility, proliferation and differentiation (Heldin and Lennartsson, 2013). In this 
chapter, we identified that LAR positively regulates PDGFβR tyrosine 
phosphorylation and the activation of downstream proteins (Figure 7.1 and 7.4). 
Having identified LAR potentiates PDGFβR tyrosine autophosphorylation and 
positivity regulates canonical PDGF signalling pathways such as mTOR and JNK 
(Chapter 3), we further investigated the underling mechanism. We have shown that 
LAR is directly regulates c-Abl activity by mediating the dephosphorylation of 
tyrosine residues on c-Abl (Chapter 4). This suggests that, in LARΔP cells, the higher 
c-Abl activity leads to either a direct modulation of PDGFβR activity or an indirect 
mechanism involving regulation of activity of downstream targets involved in 
attenuating PDGF signalling. One of the possibilities is the phosphorylation of serine 
residues on PDGFβR which in turn leads to reduced tyrosine phosphorylation and 
kinase activity. For example, GRK2 has been shown to regulate PDGFβR by 
mediating serine phosphorylation (Hildreth et al., 2004).  
It has shown that the activation of MAP kinase promotes GRK2 degradation (Elorza 
et al., 2003). In addition, ERK1 has reported to deactivate GRK2 by the 
phosphorylation of Ser670 (Elorza et al., 2000, Pitcher et al., 1999). Quantitative 
proteomics revealed a significant increase in the phosphorylation of GRK2 at Ser670 in 
WT cells following PDGF stimulation (Figure 7.3). GRK2 was highly tyrosine 
phosphorylated in LARΔP MEFs, further indicating that LAR controls the activity of 
GRK2 (Figure 7.2). Furthermore, the finding that knockdown of GRK2 restored the 
activity of PDGFβR downstream kinases, Akt and ERK1/2 (Figure 7.4) suggests that 
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LAR keeps c-Abl and GRK2 inactive leading to enhanced and prolonged PDGFβR 
autophosphorylation and activation. This would be consistent with the observation that 
loss of LAR activity was accompanied by decreased ERK1/2 phosphorylation, which 
would remove the inhibitory effect of ERK1/2 on GRK2, leading to activation of 
GRK2 and inactivation of PDGFβR. This is supported by the observation that in WT 
cells, ERK1/2 was highly activated, with less GRK2 activity, indicating that LAR 
enhances PDGFβR activity through suppression of GRK2 activity.  
We also detected the interaction of NHERF2 with PDGFβR in WT cells following 
PDGF stimulation (Figure 7.5). Taken together, these data suggest that LAR regulates 
PDGFβR by inhibition of GRK2 activity which affects association of NHERF2 with 
PDGFβR, leading to stabilized the receptor dimerization, enhancing the tyrosine 
autophosphorylation and downstream signalling molecules. In summary, we propose 
a novel mechanism whereby LAR enhances PDGFβR signalling through suppression 
of GRK2.  
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CHAPTER 8 
 
Discussion and Future Directions 
	
 
Platelet-derived growth factors are known to stimulate of multiple cellular functions 
in cells of mesenchymal origin. PDGFs and their receptors are expressed in most 
tissues and play important roles during embryonic development leading to cell 
proliferation and differentiation (Heldin and Westermark, 1999). In addition, PDGFs 
also play a crucial post-natal role regulating wound healing, constriction of blood 
vessels, angiogenesis, cell migration, chemotaxis and tissue remodeling (Fredriksson 
et al., 2004, Hansen et al., 1996, Hellberg et al., 2010). 
PDGF receptor overactivation has been linked to several diseases including breast 
cancer, glioblastoma, sarcoma, atherosclerosis and renal fibrosis (Aguilar, 2016, 
Alehagen et al., 2016, Appiah-Kubi et al., 2016, Lewandowski et al., 2016a, 
Lewandowski et al., 2016b, Pietras et al., 2003). Furthermore, overexpression of 
PDGFβR has also reported in lung cancer, demonstrating a crucial role for PDGF in 
the development of lung cancer (Tsao et al., 2011). Taken together, these findings 
demonstrate that PDGF receptor overactivation contributes to the development of 
cancer and invasiveness.  
PDGFβR signalling is highly controlled through several mechanisms that modulate 
the receptor activity. Dephosphorylation of the phosphorylated tyrosine residues by 
protein tyrosine phosphatases (PTPs) is one of the key mechanisms for controlling the 
receptor activity and downstream signalling pathways (Nicholas K Tonks, 2006b). It 
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has been reported that many PTPs directly dephosphorylate selected tyrosine residues 
on PDGFβR to terminate the receptor downstream signalling molecules. For instance, 
low molecular weight protein tyrosine phosphatase (LMW-PTP) has been found to 
dephosphorylate Tyr716 and Tyr857 on PDGFβR to inhibit the receptor kinase activity 
and prevent the interaction of Grb2 with receptor (Chiarugi et al., 2002). T-cell protein 
tyrosine phosphatase (TC-PTP) can dephosphorylate Tyr1021 on PDGFβR, which is a 
binding site of phospholipase C gamma1 (PLCγ1), leading to decreased cell migration 
in response to PDGF stimulation (Persson et al., 2004). Tyrosine-protein phosphatase 
non-receptor type 11 (SHP-2) can dephosphorylate the binding site of Ras-GAP Tyr771 
leading to enhanced activity of the Ras signalling pathway by preventing Ras-GAP 
interacting with PDGFβR (Ekman et al., 2002). Moreover, PTP1B dephosphorylates 
Tyr579 residue of PDGFβR where Src and Shc can bind, to terminate the signalling 
initiation by these proteins (Ekman et al., 2002, Persson et al., 2004). Finally histidine 
domain-containing protein tyrosine phosphatase (HD-PTP) is recruited to PDGFβR in 
response to PDGF-BB and is required for PDGFβR degradation  (H. Ma et al., 2015a). 
In this thesis, global SILAC-based phosphoproteomics approach was applied to gain 
insight into the signal transduction pathways regulated by PDGF. In addition, this 
technique was used in combination with bioinformatics and computational biology to 
study the role for the one of receptor-type protein tyrosine phosphatase (LAR) on 
PDGFβR downstream signalling pathways and PDGF-induced cellular functions 
including cell adhesion, migration and proliferation. This type of comprehensive 
analysis of the LAR regulated phosphoproteome in response to PDGF stimulation has 
not been done before.  
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A total of 29,734 phosphopeptides were identified across the four biological replicates 
including redundant and non-redundant peptides. In LARDP cells, a total of 270 
phosphopeptides from 205 proteins showed a significant change in abundance 
(p<0.05; >1.5-fold change) upon PDGF stimulation. Of these, 255 (95%) are serine 
phosphorylation sites, 9 (3%) threonine, and 6 (2%) were tyrosine phosphorylation 
sites indicating that LAR could contribute to the regulation of these phosphorylation 
sites via modulation of the activity of specific kinases, or via direct dephosphorylation 
of the tyrosine sites. 
Most of the previous studies on LAR were focused on its role in the regulation of the 
nervous system including neuronal development, growth, neuronal regeneration and 
axon guidance (Mélanie J Chagnon et al., 2004a, Sethi et al., 2010, Fang Wang et al., 
2012, Julie S Zhang and Longo, 1995). However, GO term analysis revealed an 
enrichment of LAR-mediated phosphorylation events on proteins involved in many 
signal transduction pathways affecting the actin cytoskeleton, cell adhesion, 
endocytosis and metabolism. Kinase prediction tools have identified a key role for 
LAR in regulating ERK, mTOR and JNK signalling pathways in response to PDGF 
stimulation. These data have been confirmed by immunoblotting. Importantly, re-
expression of WT LAR in LARDP MEFs rescued the activity of these signalling 
pathways, providing further support that PDGF-induced mTOR, ERK and JNK 
pathways is LAR-dependent phenotype.  Collectively, these results significantly 
expand the range of proteins implicated downstream of LAR and provide an extensive 
publicly available dataset for further scrutiny.  
The activity of GRK2 was higher in LARDP MEFs. GRK2 is a serine/threonine kinase 
that has previously been shown to regulate PDGFβR by mediating serine 
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phosphorylation (Hildreth et al., 2004). ERK has been reported to downregulate GRK2 
activity through phosphorylation of Ser670 (Elorza et al., 2000, Pitcher et al., 1999). 
Quantitative proteomics revealed a significant increase in the phosphorylation of 
GRK2 at Ser670 in WT cells following PDGF stimulation and this supports the notion 
that GRK2 is overactivated in LARDP MEFs. A possible explanation for this might be 
that LAR is regulating PDGFβR signalling through the inhibition of GRK2 activity 
since the knockdown of this protein partially restored the activity of ERK1/2 and Akt 
in LARDP cells. Another possible explanation for this is that loss of LAR activity in 
LARDP MEFs was accompanied by decreased ERK1/2 activity, which would remove 
the inhibitory effect of ERK1/2 on GRK2, leading to GRK2 activation, which in turn 
phosphorylates serine residues on the PDGFβR. This is also supported by the 
observation that in WT cells, ERK1/2 was highly activated, with less GRK2 activity, 
indicating that LAR enhances PDGFβR downstream signalling through the 
suppression of GRK2 activity. Further work is required to establish the regulation of 
GRK2 by LAR. Is it direct tyrosine dephosphorylation or indirectly via mediator 
proteins? To answer these questions, quantitative phosphoproteomics and mutation 
approaches could be used to map the phosphorylation of tyrosine residues on GRK2 
and identify which site is regulated by LAR. Further research should be also 
undertaken to investigate the biological functions of these sites. In addition, CRISPR-
Cas9 approach could be used to knockout LAR in mammalian cells to better 
understand the role of LAR in regulation of signal transduction pathways. 
Actin cytoskeleton and cell adhesion were the most predominant GO terms identified 
in the phosphoproteome data set. Therefore, we decided to investigate if LAR 
regulates cell adhesion. Decreased adhesion complex formation and cell adhesion to 
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fibronectin were observed in LARDP MEFs, identifying a novel role for LAR as a 
regulator of cell adhesion in mammalian cells. It was further investigated the underling 
mechanism on how LAR regulates cell adhesion. Kinase motifs analysis of 
phosphoproteome data set identified CDK1 as a predominant node and predicated to 
phosphorylate the majority of phosphosites. In addition, CDK1 activity was essential 
for the formation of focal adhesion complexes. By using LAR substrate-tapping 
mutants, this phenotype is mainly regulated through c-Abl-Akt pathway. Since the 
inhibition of c-Abl can restored the activity of Akt and CDK1 in LARDP cells. Akt1 
has previously been shown to be required for phosphorylation of CDK1 at Thr161 
(Nogueira et al., 2012). It is possible, therefore, that Akt acts a downstream of LAR 
and c-Abl leading to activation of CDK1 and promoting the formation of focal 
adhesions. Taken together, these findings reveal a novel pathway downstream of LAR 
that regulates cell adhesion in c-Abl, Akt and CDK1 dependent manner.  
In future work, it would be interesting to study if LAR regulates cell adhesion to other 
extracellular proteins such as collagen or laminin. Total Internal Reflection 
Fluorescence (TIRF) microscopy technique can be used to study if LAR colocalize 
with cell adhesion proteins such as paxillin, talin or vinculin in presence and absent of 
PDGF. We identified a connection between LAR and integrin expression in the 
phosphoproteomics data set. It would be interesting to assess the effects of LAR on 
integrin expression and whether LAR enhances cell adhesion or other function via 
integrin interaction. This may allow whether LAR involved in metastasis since 
integrins regulate many cellular functions that are crucial to the initiation and 
progression of cancer. If LAR regulates integrin expression, then LAR protein can be 
used as a cancer biomarker.  
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Part of the work presented in this thesis provides the first systematic study of PDGF 
signalling using a quantitative phosphoproteomics approach. In total, 989 
phosphosites from 611 proteins were detected in response to PDGF stimulation. 
Within the phosphoproteome dataset, the phosphosites comprised 896 (90.6%) serine, 
76 (7.6%) threonine and 17 (1.7%) tyrosine phosphorylation sites. Of these, 161 
phosphorylation sites showed a significant change in abundance (p <0.05; >1.5-fold 
change). Interestingly, from 161 phosphosites, 110 (67%) have not been reported as 
PDGF-regulated sites and are considered novel. These results significantly expand the 
range of proteins implicated in PDGF signalling pathways.  
PDGF-induced cell migration has been widely studied and involves the small GTPase 
Rac1, ERK MAPK and JNK kinases (Doanes et al., 1998, Ridley et al., 1992, Zhan et 
al., 2003). The identification of CRMP2 as a PDGF-stimulated regulator of cell 
migration adds another effector to this list. CRMP2 is dephosphorylated in response 
to PDGFbR activation and is required for PDGF-induced cell migration. It is possible 
that PDGFbR modulates the activity of CRMP2 via an unknown adaptor protein. 
Another possible explanation for these findings is that PDGFbR activates serine/ 
threonine phosphatases that then dephosphorylate CRMP2 at Thr514 leading to 
activation. This explanation is supported by the fact that inhibition of protein 
phosphatase 1 (PP1) can restored the phosphorylation of Thr514 on CRMP2 upon 
PDGF stimulation. Further work is needed to identify how PDGFbR is involved in 
regulation of PP1 activity. 
The proteome datasets were analysed in order to identify protein expression regulated 
by LAR. Within the proteomic data set, a total of 2939 proteins were identified. Of 
these, 147 proteins showed a significant change in abundance in LARDP MEFs 
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compared with the WT. GO terms analysis of these proteins revealed enrichment of 
metabolic processes. Therefore, we examined the role of LAR in mitochondrial 
respiration. Higher mitochondrial respiration was observed in LARDP MEFs 
compared with WT suggesting that LAR could suppresses mitochondrial respiration 
by regulating protein turnover. Immunoblotting analysis identified overexpression of 
succinate dehydrogenase subunit b (Sdhb) in LARDP cells when compared with WT 
cells. The evidence from this study suggests that LAR could decrease mitochondrial 
respiration through regulation of Sdhb expression. However, further studies are 
required to confirm and validate these findings. For instance, it would be interesting 
to study if LAR localizes to mitochondria, as there is mass spectrometry evidence 
showing that LAR can be found in mitochondria (Smith and Robinson, 2016, Stauch 
et al., 2014). In addition, different LAR constructs could be expressed to identify 
which domains are responsible for suppressing mitochondrial activity. Further 
research is also required to determine whether LAR can regulate protein turnover or 
mRNA level to modulate energetic homeostasis. 
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